<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37433768</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-3635</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>Signal transduction and targeted therapy</Title><ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation></Journal><ArticleTitle>Role of neuroinflammation in neurodegeneration development.</ArticleTitle><Pagination><StartPage>267</StartPage><MedlinePgn>267</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">267</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-023-01486-5</ELocationID><Abstract><AbstractText>Studies in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis, Huntington's disease, and so on, have suggested that inflammation is not only a result of neurodegeneration but also a crucial player in this process. Protein aggregates which are very common pathological phenomenon in neurodegeneration can induce neuroinflammation which further aggravates protein aggregation and neurodegeneration. Actually, inflammation even happens earlier than protein aggregation. Neuroinflammation induced by genetic variations in CNS cells or by peripheral immune cells may induce protein deposition in some susceptible population. Numerous signaling pathways and a range of CNS cells have been suggested to be involved in the pathogenesis of neurodegeneration, although they are still far from being completely understood. Due to the limited success of traditional treatment methods, blocking or enhancing inflammatory signaling pathways involved in neurodegeneration are considered to be promising strategies for the therapy of neurodegenerative diseases, and many of them have got exciting results in animal models or clinical trials. Some of them, although very few, have been approved by FDA for clinical usage. Here we comprehensively review the factors affecting neuroinflammation and the major inflammatory signaling pathways involved in the pathogenicity of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis. We also summarize the current strategies, both in animal models and in the clinic, for the treatment of neurodegenerative diseases.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Weifeng</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-6176-4907</Identifier><AffiliationInfo><Affiliation>Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, 199 South Chang'an Road, Xi'an, 710062, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xiao</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The State Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Air Force Medical University, No. 169 Changle West Road, Xi'an, 710032, P.R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Burns and Cutaneous Surgery, Xijing Hospital, Air Force Medical University, No. 169 Changle West Road, Xi'an, 710032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qinwen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Utah, Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT, 84112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Haibin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2038-5759</Identifier><AffiliationInfo><Affiliation>Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, 199 South Chang'an Road, Xi'an, 710062, P.R. China. hbxia2001@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Signal Transduct Target Ther</MedlineTA><NlmUniqueID>101676423</NlmUniqueID><ISSNLinking>2059-3635</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37433768</ArticleId><ArticleId IdType="pmc">PMC10336149</ArticleId><ArticleId IdType="doi">10.1038/s41392-023-01486-5</ArticleId><ArticleId IdType="pii">10.1038/s41392-023-01486-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mayne K, White JA, McMurran CE, Rivera FJ, de la Fuente AG. Aging and neurodegenerative disease: is the adaptive immune system a friend or foe? Front. Aging Neurosci. 2020;12:572090. doi: 10.3389/fnagi.2020.572090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.572090</ArticleId><ArticleId IdType="pmc">PMC7538701</ArticleId><ArticleId IdType="pubmed">33173502</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 2002;14:223&#x2013;236. doi: 10.1176/jnp.14.2.223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/jnp.14.2.223</ArticleId><ArticleId IdType="pubmed">11983801</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG. The history of Parkinson&#x2019;s disease: early clinical descriptions and neurological therapies. Cold Spring Harb. Perspect. Med. 2011;1:a008862. doi: 10.1101/cshperspect.a008862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a008862</ArticleId><ArticleId IdType="pmc">PMC3234454</ArticleId><ArticleId IdType="pubmed">22229124</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer&#x2019;s disease. Neurobiol. Aging. 1988;9:339&#x2013;349. doi: 10.1016/S0197-4580(88)80079-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(88)80079-4</ArticleId><ArticleId IdType="pubmed">3263583</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy PE, Rapport M, Graf L. Glial fibrillary acidic protein and Alzheimer-type senile dementia. Neurology. 1980;30:778&#x2013;782. doi: 10.1212/WNL.30.7.778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.30.7.778</ArticleId><ArticleId IdType="pubmed">7190246</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson&#x2019;s and Alzheimer&#x2019;s disease brains. Neurology. 1988;38:1285&#x2013;1291. doi: 10.1212/WNL.38.8.1285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.38.8.1285</ArticleId><ArticleId IdType="pubmed">3399080</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 1987;79:195&#x2013;200. doi: 10.1016/0304-3940(87)90696-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(87)90696-3</ArticleId><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 1988;76:550&#x2013;557. doi: 10.1007/BF00689592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00689592</ArticleId><ArticleId IdType="pubmed">2974227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney JW, et al. Inflammation as a central mechanism in Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;4:575&#x2013;590. doi: 10.1016/j.trci.2018.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.06.014</ArticleId><ArticleId IdType="pmc">PMC6214864</ArticleId><ArticleId IdType="pubmed">30406177</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer&#x2019;s disease. Glia. 1993;7:75&#x2013;83. doi: 10.1002/glia.440070113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.440070113</ArticleId><ArticleId IdType="pubmed">8423065</ArticleId></ArticleIdList></Reference><Reference><Citation>Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia. 1993;7:111&#x2013;118. doi: 10.1002/glia.440070117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.440070117</ArticleId><ArticleId IdType="pubmed">8423058</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, et al. Microglia in degenerative neurological disease. Glia. 1993;7:84&#x2013;92. doi: 10.1002/glia.440070114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.440070114</ArticleId><ArticleId IdType="pubmed">8423066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling EA, Wong WC. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia. 1993;7:9&#x2013;18. doi: 10.1002/glia.440070105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.440070105</ArticleId><ArticleId IdType="pubmed">8423067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration. Immunity. 2019;50:955&#x2013;974. doi: 10.1016/j.immuni.2019.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.016</ArticleId><ArticleId IdType="pmc">PMC6822103</ArticleId><ArticleId IdType="pubmed">30995509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716. doi: 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosna J, et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener. 2018;13:11. doi: 10.1186/s13024-018-0244-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0244-x</ArticleId><ArticleId IdType="pmc">PMC5831225</ArticleId><ArticleId IdType="pubmed">29490706</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, Q. et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci. Transl. Med. 9, eaaf6295 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="pubmed">28566429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007;10:1387&#x2013;1394. doi: 10.1038/nn1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1997</ArticleId><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier LP, et al. Microglial metabolic flexibility supports immune surveillance of the brain parenchyma. Nat. Commun. 2020;11:1559. doi: 10.1038/s41467-020-15267-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15267-z</ArticleId><ArticleId IdType="pmc">PMC7096448</ArticleId><ArticleId IdType="pubmed">32214088</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright, F., Chan, G., van Hummel, A., Ittner, L. M. &amp; Ke, Y. D. TDP-43 and Inflammation: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Int. J. Mol. Sci. 22, 7781 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8346169</ArticleId><ArticleId IdType="pubmed">34360544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mou Y, et al. Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging. Front. Immunol. 2022;13:796288. doi: 10.3389/fimmu.2022.796288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.796288</ArticleId><ArticleId IdType="pmc">PMC9021448</ArticleId><ArticleId IdType="pubmed">35464431</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Kim CH. Regulation of common neurological disorders by gut microbial metabolites. Exp. Mol. Med. 2021;53:1821&#x2013;1833. doi: 10.1038/s12276-021-00703-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00703-x</ArticleId><ArticleId IdType="pmc">PMC8741890</ArticleId><ArticleId IdType="pubmed">34857900</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrattan, A., Stewart, C. J., Cassidy, A., Woodside, J. V. &amp; McEvoy, C. T. Diet patterns, the gut microbiome, and Alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis. 88, 933-941 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35634849</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, et al. Progranulin deficiency promotes persistent neuroinflammation and causes regional pathology in the hippocampus following traumatic brain injury. Glia. 2022;70:1317&#x2013;1336. doi: 10.1002/glia.24175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.24175</ArticleId><ArticleId IdType="pubmed">35362178</ArticleId></ArticleIdList></Reference><Reference><Citation>Duro MV, Ebright B, Yassine HN. Lipids and brain inflammation in APOE4-associated dementia. Curr. Opin. Lipidol. 2022;33:16&#x2013;24. doi: 10.1097/MOL.0000000000000801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0000000000000801</ArticleId><ArticleId IdType="pmc">PMC8769806</ArticleId><ArticleId IdType="pubmed">34907965</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 2014;33:7&#x2013;22. doi: 10.1002/embj.201386609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/embj.201386609</ArticleId><ArticleId IdType="pmc">PMC3990679</ArticleId><ArticleId IdType="pubmed">24357543</ArticleId></ArticleIdList></Reference><Reference><Citation>2020 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 17, 327-406 (2020).</Citation></Reference><Reference><Citation>Otani K, Shichita T. Cerebral sterile inflammation in neurodegenerative diseases. Inflamm. Regen. 2020;40:28. doi: 10.1186/s41232-020-00137-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-020-00137-4</ArticleId><ArticleId IdType="pmc">PMC7722432</ArticleId><ArticleId IdType="pubmed">33292860</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367. doi: 10.1016/S1474-4422(13)70044-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70044-9</ArticleId><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013;80:890&#x2013;896. doi: 10.1212/WNL.0b013e3182840bbe.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182840bbe</ArticleId><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014;14:463&#x2013;477. doi: 10.1038/nri3705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3705</ArticleId><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnerbauer M, Wheeler MA, Quintana FJ. Astrocyte crosstalk in CNS inflammation. Neuron. 2020;108:608&#x2013;622. doi: 10.1016/j.neuron.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7704785</ArticleId><ArticleId IdType="pubmed">32898475</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyango, I. G., Jauregui, G. V., Carna, M., Bennett, J. P., Jr. &amp; Stokin, G. B. Neuroinflammation in Alzheimer&#x2019;s disease. Biomedicines9, 524 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8150909</ArticleId><ArticleId IdType="pubmed">34067173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer&#x2019;s disease. J. Cell Biol. 2018;217:459&#x2013;472. doi: 10.1083/jcb.201709069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201709069</ArticleId><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini E, D&#x2019;Angelo C, Reale M. The role of immunosenescence in neurodegenerative diseases. Mediators Inflamm. 2018;2018:6039171. doi: 10.1155/2018/6039171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6039171</ArticleId><ArticleId IdType="pmc">PMC5863336</ArticleId><ArticleId IdType="pubmed">29706800</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Baron P, Scarlato G. Glial activation in Alzheimer&#x2019;s disease: the role of Abeta and its associated proteins. Neurobiol. Aging. 2001;22:885&#x2013;893. doi: 10.1016/S0197-4580(01)00307-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00307-4</ArticleId><ArticleId IdType="pubmed">11754995</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan ZS, Seshadri S. Inflammation in the Alzheimer&#x2019;s disease cascade: culprit or innocent bystander? Alzheimers Res. Ther. 2010;2:6. doi: 10.1186/alzrt29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt29</ArticleId><ArticleId IdType="pmc">PMC2876784</ArticleId><ArticleId IdType="pubmed">20388190</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur JY, et al. The innate immunity protein IFITM3 modulates gamma-secretase in Alzheimer&#x2019;s disease. Nature. 2020;586:735&#x2013;740. doi: 10.1038/s41586-020-2681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2681-2</ArticleId><ArticleId IdType="pmc">PMC7919141</ArticleId><ArticleId IdType="pubmed">32879487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisbet RM, Polanco JC, Ittner LM, Gotz J. Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol. 2015;129:207&#x2013;220. doi: 10.1007/s00401-014-1371-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1371-2</ArticleId><ArticleId IdType="pmc">PMC4305093</ArticleId><ArticleId IdType="pubmed">25492702</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Maphis N, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138:1738&#x2013;1755. doi: 10.1093/brain/awv081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv081</ArticleId><ArticleId IdType="pmc">PMC4542622</ArticleId><ArticleId IdType="pubmed">25833819</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133:665&#x2013;704. doi: 10.1007/s00401-017-1707-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1707-9</ArticleId><ArticleId IdType="pmc">PMC5390006</ArticleId><ArticleId IdType="pubmed">28386764</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe EA, et al. Inflammation: the link between comorbidities, genetics, and Alzheimer&#x2019;s disease. J. Neuroinflamm. 2018;15:276. doi: 10.1186/s12974-018-1313-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1313-3</ArticleId><ArticleId IdType="pmc">PMC6154824</ArticleId><ArticleId IdType="pubmed">30249283</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, et al. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer&#x2019;s disease. Brain. 2018;141:2740&#x2013;2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">30052812</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng JX, et al. Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses. Nat. Commun. 2022;13:2692. doi: 10.1038/s41467-022-30461-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30461-x</ArticleId><ArticleId IdType="pmc">PMC9110413</ArticleId><ArticleId IdType="pubmed">35577786</ArticleId></ArticleIdList></Reference><Reference><Citation>Welikovitch LA, et al. Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proc. Natl Acad. Sci. USA. 2020;117:6844&#x2013;6854. doi: 10.1073/pnas.1914593117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1914593117</ArticleId><ArticleId IdType="pmc">PMC7104377</ArticleId><ArticleId IdType="pubmed">32144141</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C, Heneka MT. Danger-associated molecular patterns in Alzheimer&#x2019;s disease. J. Leukoc. Biol. 2017;101:87&#x2013;98. doi: 10.1189/jlb.3MR0416-204R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.3MR0416-204R</ArticleId><ArticleId IdType="pubmed">28049142</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey MG, et al. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 2022;22:657&#x2013;673. doi: 10.1038/s41577-022-00684-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00684-6</ArticleId><ArticleId IdType="pmc">PMC8895080</ArticleId><ArticleId IdType="pubmed">35246670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson&#x2019;s disease. Brain. 2013;136:2419&#x2013;2431. doi: 10.1093/brain/awt192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt192</ArticleId><ArticleId IdType="pmc">PMC3722357</ArticleId><ArticleId IdType="pubmed">23884810</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen V. Parkinson&#x2019;s disease: can targeting inflammation be an effective neuroprotective strategy? Front. Neurosci. 2020;14:580311. doi: 10.3389/fnins.2020.580311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.580311</ArticleId><ArticleId IdType="pmc">PMC7946840</ArticleId><ArticleId IdType="pubmed">33716638</ArticleId></ArticleIdList></Reference><Reference><Citation>Milber JM, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology. 2012;79:2307&#x2013;2314. doi: 10.1212/WNL.0b013e318278fe32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318278fe32</ArticleId><ArticleId IdType="pmc">PMC3578379</ArticleId><ArticleId IdType="pubmed">23152586</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949&#x2013;953. doi: 10.1126/science.1227157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227157</ArticleId><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson&#x2019;s disease. FASEB J. 2005;19:533&#x2013;542. doi: 10.1096/fj.04-2751com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.04-2751com</ArticleId><ArticleId IdType="pubmed">15791003</ArticleId></ArticleIdList></Reference><Reference><Citation>Acuna L, et al. Rifampicin and its derivative rifampicin quinone reduce microglial inflammatory responses and neurodegeneration induced in vitro by alpha-synuclein fibrillary aggregates. Cells. 2019;8:776. doi: 10.3390/cells8080776.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8080776</ArticleId><ArticleId IdType="pmc">PMC6721546</ArticleId><ArticleId IdType="pubmed">31349736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludtmann MHR, et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson&#x2019;s disease. Nat. Commun. 2018;9:2293. doi: 10.1038/s41467-018-04422-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04422-2</ArticleId><ArticleId IdType="pmc">PMC5997668</ArticleId><ArticleId IdType="pubmed">29895861</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maio R, et al. alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson&#x2019;s disease. Sci. Transl. Med. 2016;8:342ra378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016095</ArticleId><ArticleId IdType="pubmed">27280685</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy MF, et al. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J. Neuroinflamm. 2018;15:129. doi: 10.1186/s12974-018-1171-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1171-z</ArticleId><ArticleId IdType="pmc">PMC5930695</ArticleId><ArticleId IdType="pubmed">29716614</ArticleId></ArticleIdList></Reference><Reference><Citation>Krashia P, et al. Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson&#x2019;s disease. Nat. Commun. 2019;10:3945. doi: 10.1038/s41467-019-11928-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11928-w</ArticleId><ArticleId IdType="pmc">PMC6718379</ArticleId><ArticleId IdType="pubmed">31477726</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale A, Calabrese V. The intricate debate on neurodegeneration and neuroinflammation in Parkinson&#x2019;s disease: which came first? Neural Regen. Res. 2023;18:125&#x2013;126. doi: 10.4103/1673-5374.343895.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.343895</ArticleId><ArticleId IdType="pmc">PMC9241404</ArticleId><ArticleId IdType="pubmed">35799526</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 2013;4:1562. doi: 10.1038/ncomms2534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2534</ArticleId><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi I, et al. Microglia clear neuron-released alpha-synuclein via selective autophagy and prevent neurodegeneration. Nat. Commun. 2020;11:1386. doi: 10.1038/s41467-020-15119-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15119-w</ArticleId><ArticleId IdType="pmc">PMC7069981</ArticleId><ArticleId IdType="pubmed">32170061</ArticleId></ArticleIdList></Reference><Reference><Citation>Grozdanov V, et al. Increased immune activation by pathologic alpha-synuclein in Parkinson&#x2019;s disease. Ann. Neurol. 2019;86:593&#x2013;606. doi: 10.1002/ana.25557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25557</ArticleId><ArticleId IdType="pubmed">31343083</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavarria C, Ivagnes R, Souza JM. Extracellular alpha-synuclein: mechanisms for glial cell internalization and activation. Biomolecules. 2022;12:655. doi: 10.3390/biom12050655.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12050655</ArticleId><ArticleId IdType="pmc">PMC9138387</ArticleId><ArticleId IdType="pubmed">35625583</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajares M, Rojo AI, Manda, Bosca L, Cuadrado A. Inflammation in Parkinson&#x2019;s disease: mechanisms and therapeutic implications. Cells. 2020;9:1687. doi: 10.3390/cells9071687.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071687</ArticleId><ArticleId IdType="pmc">PMC7408280</ArticleId><ArticleId IdType="pubmed">32674367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahata I, Finkelstein DI, Fukunaga K. Pathogenic impact of alpha-synuclein phosphorylation and its kinases in alpha-synucleinopathies. Int. J. Mol. Sci. 2022;23:6216. doi: 10.3390/ijms23116216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23116216</ArticleId><ArticleId IdType="pmc">PMC9181156</ArticleId><ArticleId IdType="pubmed">35682892</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimer L, et al. Inflammation kinase PKR phosphorylates alpha-synuclein and causes alpha-synuclein-dependent cell death. Neurobiol. Dis. 2018;115:17&#x2013;28. doi: 10.1016/j.nbd.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.03.001</ArticleId><ArticleId IdType="pubmed">29501855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanem SS, et al. alpha-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl Acad. Sci. USA. 2022;119:e2109617119. doi: 10.1073/pnas.2109617119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109617119</ArticleId><ArticleId IdType="pmc">PMC9169642</ArticleId><ArticleId IdType="pubmed">35353605</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasen A, et al. Upregulation of alpha-synuclein following immune activation: possible trigger of Parkinson&#x2019;s disease. Neurobiol. Dis. 2022;166:105654. doi: 10.1016/j.nbd.2022.105654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105654</ArticleId><ArticleId IdType="pubmed">35143968</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y, et al. Reactive microglia enhance the transmission of exosomal alpha-synuclein via toll-like receptor 2. Brain. 2021;144:2024&#x2013;2037. doi: 10.1093/brain/awab122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab122</ArticleId><ArticleId IdType="pubmed">33792662</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Savolainen M, Chu Y, Halliday GM, Kordower JH. Temporal evolution of microglia and alpha-synuclein accumulation following foetal grafting in Parkinson&#x2019;s disease. Brain. 2019;142:1690&#x2013;1700. doi: 10.1093/brain/awz104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz104</ArticleId><ArticleId IdType="pubmed">31056668</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiblich H, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184:5089&#x2013;5106.e5021. doi: 10.1016/j.cell.2021.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.09.007</ArticleId><ArticleId IdType="pmc">PMC8527836</ArticleId><ArticleId IdType="pubmed">34555357</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami J, et al. Crosstalk between astrocytes and microglia results in increased degradation of alpha-synuclein and amyloid-beta aggregates. J. Neuroinflamm. 2021;18:124. doi: 10.1186/s12974-021-02158-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02158-3</ArticleId><ArticleId IdType="pmc">PMC8173980</ArticleId><ArticleId IdType="pubmed">34082772</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D, et al. T cells from patients with Parkinson&#x2019;s disease recognize alpha-synuclein peptides. Nature. 2017;546:656&#x2013;661. doi: 10.1038/nature22815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22815</ArticleId><ArticleId IdType="pmc">PMC5626019</ArticleId><ArticleId IdType="pubmed">28636593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindestam Arlehamn CS, et al. alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson&#x2019;s disease. Nat. Commun. 2020;11:1875. doi: 10.1038/s41467-020-15626-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15626-w</ArticleId><ArticleId IdType="pmc">PMC7171193</ArticleId><ArticleId IdType="pubmed">32313102</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari AA, et al. Neurodegeneration by alpha-synuclein-specific T cells in AAV-A53T-alpha-synuclein Parkinson&#x2019;s disease mice. Brain Behav. Immun. 2022;101:194&#x2013;210. doi: 10.1016/j.bbi.2022.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.01.007</ArticleId><ArticleId IdType="pubmed">35032575</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918&#x2013;934. doi: 10.1016/j.cell.2010.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.02.016</ArticleId><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front. Immunol. 2017;8:1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiol. 2015;7:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CH, et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649.e618. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Calio ML, et al. Mitochondrial dysfunction, neurogenesis, and epigenetics: putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front. Neurosci. 2020;14:679. doi: 10.3389/fnins.2020.00679.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00679</ArticleId><ArticleId IdType="pmc">PMC7373761</ArticleId><ArticleId IdType="pubmed">32760239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, et al. TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. Exp. Neurol. 2015;273:24&#x2013;35. doi: 10.1016/j.expneurol.2015.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.07.019</ArticleId><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 2006;9:108&#x2013;118. doi: 10.1038/nn1603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1603</ArticleId><ArticleId IdType="pubmed">16369483</ArticleId></ArticleIdList></Reference><Reference><Citation>Beland LC, et al. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2020;2:fcaa124. doi: 10.1093/braincomms/fcaa124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa124</ArticleId><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013;81:1222&#x2013;1225. doi: 10.1212/WNL.0b013e3182a6cc13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CY, Yang TM, Ou RW, Wei QQ, Shang HF. Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases. BMC Med. 2021;19:27. doi: 10.1186/s12916-021-01903-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-01903-y</ArticleId><ArticleId IdType="pmc">PMC7863260</ArticleId><ArticleId IdType="pubmed">33541344</ArticleId></ArticleIdList></Reference><Reference><Citation>Djordjevic J, Sabbir MG, Albensi BC. Traumatic brain injury as a risk factor for Alzheimer&#x2019;s disease: is inflammatory signaling a key player? Curr. Alzheimer Res. 2016;13:730&#x2013;738. doi: 10.2174/1567205013666160222110320.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666160222110320</ArticleId><ArticleId IdType="pubmed">26899581</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer&#x2019;s disease? Nat. Rev. Neurosci. 2010;11:361&#x2013;370. doi: 10.1038/nrn2808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2808</ArticleId><ArticleId IdType="pmc">PMC3979339</ArticleId><ArticleId IdType="pubmed">20216546</ArticleId></ArticleIdList></Reference><Reference><Citation>Delic V, Beck KD, Pang KCH, Citron BA. Biological links between traumatic brain injury and Parkinson&#x2019;s disease. Acta Neuropathol. Commun. 2020;8:45. doi: 10.1186/s40478-020-00924-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00924-7</ArticleId><ArticleId IdType="pmc">PMC7137235</ArticleId><ArticleId IdType="pubmed">32264976</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz CK, et al. Impact of traumatic brain injury on amyotrophic lateral sclerosis: from bedside to bench. J. Neurophysiol. 2019;122:1174&#x2013;1185. doi: 10.1152/jn.00572.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00572.2018</ArticleId><ArticleId IdType="pmc">PMC6766734</ArticleId><ArticleId IdType="pubmed">31116639</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KA, et al. Systemic inflammation during midlife and cognitive change over 20 years: the ARIC study. Neurology. 2019;92:e1256&#x2013;e1267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511107</ArticleId><ArticleId IdType="pubmed">30760633</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KA, et al. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC study. Neurology. 2017;89:2262&#x2013;2270. doi: 10.1212/WNL.0000000000004688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004688</ArticleId><ArticleId IdType="pmc">PMC5705246</ArticleId><ArticleId IdType="pubmed">29093073</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Van Hoecke L, Vandenbroucke RE. The impact of systemic inflammation on Alzheimer&#x2019;s disease pathology. Front. Immunol. 2021;12:796867. doi: 10.3389/fimmu.2021.796867.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.796867</ArticleId><ArticleId IdType="pmc">PMC8770958</ArticleId><ArticleId IdType="pubmed">35069578</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S, Fu Z, Kipnis J. The meningeal lymphatic system: a new player in neurophysiology. Neuron. 2018;100:375&#x2013;388. doi: 10.1016/j.neuron.2018.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.09.022</ArticleId><ArticleId IdType="pmc">PMC6268162</ArticleId><ArticleId IdType="pubmed">30359603</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J, Kipnis J. Brain borders at the central stage of neuroimmunology. Nature. 2022;612:417&#x2013;429. doi: 10.1038/s41586-022-05474-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05474-7</ArticleId><ArticleId IdType="pmc">PMC10205171</ArticleId><ArticleId IdType="pubmed">36517712</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Raposo C. Protective autoimmunity: a unifying model for the immune network involved in CNS repair. Neuroscientist. 2014;20:343&#x2013;358. doi: 10.1177/1073858413516799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858413516799</ArticleId><ArticleId IdType="pubmed">24395337</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyne RJ, Noyce AJ, Byrne M, Savica R, Marras C. Infection and risk of Parkinson&#x2019;s disease. J. Parkinsons Dis. 2021;11:31&#x2013;43. doi: 10.3233/JPD-202279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-202279</ArticleId><ArticleId IdType="pmc">PMC7990414</ArticleId><ArticleId IdType="pubmed">33361610</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanedo-Vazquez D, Bosque-Varela P, Sainz-Pelayo A, Riancho J. Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration. J. Neurol. 2019;266:27&#x2013;36. doi: 10.1007/s00415-018-8919-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8919-3</ArticleId><ArticleId IdType="pubmed">29845377</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionisio-Santos DA, Olschowka JA, O&#x2019;Banion MK. Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer&#x2019;s disease. J. Neuroinflamm. 2019;16:74. doi: 10.1186/s12974-019-1453-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1453-0</ArticleId><ArticleId IdType="pmc">PMC6449993</ArticleId><ArticleId IdType="pubmed">30953557</ArticleId></ArticleIdList></Reference><Reference><Citation>Licastro F, Porcellini E. Activation of endogenous retrovirus, brain infections and environmental insults in neurodegeneration and Alzheimer&#x2019;s disease. Int. J. Mol. Sci. 2021;22:7263. doi: 10.3390/ijms22147263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22147263</ArticleId><ArticleId IdType="pmc">PMC8303979</ArticleId><ArticleId IdType="pubmed">34298881</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Nath A, Beckham JD. Is COVID-19 a perfect storm for Parkinson&#x2019;s disease? Trends Neurosci. 2020;43:931&#x2013;933. doi: 10.1016/j.tins.2020.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.10.009</ArticleId><ArticleId IdType="pmc">PMC7577682</ArticleId><ArticleId IdType="pubmed">33158605</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo AV, et al. Microbiota-derived short chain fatty acids modulate microglia and promote Abeta plaque deposition. Elife. 2021;10:e59826. doi: 10.7554/eLife.59826.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.59826</ArticleId><ArticleId IdType="pmc">PMC8043748</ArticleId><ArticleId IdType="pubmed">33845942</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Haq R, Schlachetzki JCM, Glass CK, Mazmanian SK. Microbiome-microglia connections via the gut-brain axis. J. Exp. Med. 2019;216:41&#x2013;59. doi: 10.1084/jem.20180794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180794</ArticleId><ArticleId IdType="pmc">PMC6314531</ArticleId><ArticleId IdType="pubmed">30385457</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatterale F, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front. Physiol. 2020;10:1607. doi: 10.3389/fphys.2019.01607.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2019.01607</ArticleId><ArticleId IdType="pmc">PMC7000657</ArticleId><ArticleId IdType="pubmed">32063863</ArticleId></ArticleIdList></Reference><Reference><Citation>Litwiniuk A, Bik W, Kalisz M, Baranowska-Bik A. Inflammasome NLRP3 potentially links obesity-associated low-grade systemic inflammation and insulin resistance with Alzheimer&#x2019;s disease. Int. J. Mol. Sci. 2021;22:5603. doi: 10.3390/ijms22115603.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115603</ArticleId><ArticleId IdType="pmc">PMC8198882</ArticleId><ArticleId IdType="pubmed">34070553</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeks J, Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol. Metab. 2012;23:444&#x2013;450. doi: 10.1016/j.tem.2012.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2012.05.007</ArticleId><ArticleId IdType="pubmed">22726362</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe AM, Burke S, O&#x2019;Reilly ME, McGillicuddy FC, Costello DA. Palmitic acid and oleic acid differently modulate TLR2-mediated inflammatory responses in microglia and macrophages. Mol. Neurobiol. 2022;59:2348&#x2013;2362. doi: 10.1007/s12035-022-02756-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-022-02756-z</ArticleId><ArticleId IdType="pmc">PMC9016023</ArticleId><ArticleId IdType="pubmed">35079937</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyrolle Q, Laye S, Nadjar A. Direct and indirect effects of lipids on microglia function. Neurosci. Lett. 2019;708:134348. doi: 10.1016/j.neulet.2019.134348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.134348</ArticleId><ArticleId IdType="pubmed">31238131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon YH, et al. Hypothalamic lipid-laden astrocytes induce microglia migration and activation. FEBS Lett. 2017;591:1742&#x2013;1751. doi: 10.1002/1873-3468.12691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12691</ArticleId><ArticleId IdType="pubmed">28542876</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, et al. Glucose levels and risk of dementia. N. Engl. J. Med. 2013;369:540&#x2013;548. doi: 10.1056/NEJMoa1215740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1215740</ArticleId><ArticleId IdType="pmc">PMC3955123</ArticleId><ArticleId IdType="pubmed">23924004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahniwal M, Little JP, Klegeris A. High glucose enhances neurotoxicity and inflammatory cytokine secretion by stimulated human astrocytes. Curr. Alzheimer Res. 2017;14:731&#x2013;741. doi: 10.2174/1567205014666170117104053.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205014666170117104053</ArticleId><ArticleId IdType="pubmed">28124586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Enhancement of LPS-induced microglial inflammation response via TLR4 under high glucose conditions. Cell. Physiol. Biochem. 2015;35:1571&#x2013;1581. doi: 10.1159/000373972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000373972</ArticleId><ArticleId IdType="pubmed">25790769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayley S, Hakim AM, Albert PR. Depression, dementia and immune dysregulation. Brain. 2021;144:746&#x2013;760. doi: 10.1093/brain/awaa405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa405</ArticleId><ArticleId IdType="pmc">PMC8041341</ArticleId><ArticleId IdType="pubmed">33279966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T, et al. Systemic inflammation mediates age-related cognitive deficits. Front. Aging Neurosci. 2018;10:236. doi: 10.3389/fnagi.2018.00236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00236</ArticleId><ArticleId IdType="pmc">PMC6088306</ArticleId><ArticleId IdType="pubmed">30127734</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleidi M, Jaggle M, Rubino G. Immune aging, dysmetabolism, and inflammation in neurological diseases. Front. Neurosci. 2015;9:172. doi: 10.3389/fnins.2015.00172.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2015.00172</ArticleId><ArticleId IdType="pmc">PMC4453474</ArticleId><ArticleId IdType="pubmed">26089771</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox EG, Aburto MR, Clarke G, Cryan JF, O&#x2019;Driscoll CM. The blood-brain barrier in aging and neurodegeneration. Mol. Psychiatry. 2022;27:2659&#x2013;2673. doi: 10.1038/s41380-022-01511-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01511-z</ArticleId><ArticleId IdType="pmc">PMC9156404</ArticleId><ArticleId IdType="pubmed">35361905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P, et al. Effects of aging on blood brain barrier and matrix metalloproteases following controlled cortical impact in mice. Exp. Neurol. 2012;234:50&#x2013;61. doi: 10.1016/j.expneurol.2011.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.12.016</ArticleId><ArticleId IdType="pmc">PMC4042317</ArticleId><ArticleId IdType="pubmed">22201549</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhas PS, et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature. 2021;590:122&#x2013;128. doi: 10.1038/s41586-020-03160-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03160-0</ArticleId><ArticleId IdType="pmc">PMC8274816</ArticleId><ArticleId IdType="pubmed">33473210</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwell CS. Defining circadian disruption in neurodegenerative disorders. J. Clin. Invest. 2021;131:e148288. doi: 10.1172/JCI148288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI148288</ArticleId><ArticleId IdType="pmc">PMC8483739</ArticleId><ArticleId IdType="pubmed">34596047</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter B, Justin HS, Gulick D, Gamsby JJ. The molecular clock and neurodegenerative disease: a stressful time. Front. Mol. Biosci. 2021;8:644747. doi: 10.3389/fmolb.2021.644747.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.644747</ArticleId><ArticleId IdType="pmc">PMC8056266</ArticleId><ArticleId IdType="pubmed">33889597</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J. Clin. Investig. 2013;123:5389&#x2013;5400. doi: 10.1172/JCI70317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI70317</ArticleId><ArticleId IdType="pmc">PMC3859381</ArticleId><ArticleId IdType="pubmed">24270424</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin P, et al. REV-ERBalpha mediates complement expression and diurnal regulation of microglial synaptic phagocytosis. Elife. 2020;9:e58765. doi: 10.7554/eLife.58765.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.58765</ArticleId><ArticleId IdType="pmc">PMC7728439</ArticleId><ArticleId IdType="pubmed">33258449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kou L, et al. The circadian clock protein Rev-erbalpha provides neuroprotection and attenuates neuroinflammation against Parkinson&#x2019;s disease via the microglial NLRP3 inflammasome. J. Neuroinflamm. 2022;19:133. doi: 10.1186/s12974-022-02494-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02494-y</ArticleId><ArticleId IdType="pmc">PMC9169406</ArticleId><ArticleId IdType="pubmed">35668454</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin P, et al. Circadian clock protein Rev-erbalpha regulates neuroinflammation. Proc. Natl Acad. Sci. USA. 2019;116:5102&#x2013;5107. doi: 10.1073/pnas.1812405116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1812405116</ArticleId><ArticleId IdType="pmc">PMC6421453</ArticleId><ArticleId IdType="pubmed">30792350</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Zhang T, Lee TH. Cellular mechanisms of melatonin: insight from neurodegenerative diseases. Biomolecules. 2020;10:1158. doi: 10.3390/biom10081158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10081158</ArticleId><ArticleId IdType="pmc">PMC7464852</ArticleId><ArticleId IdType="pubmed">32784556</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo DY, Heo JW, Ko JR, Kwak HB. Exercise and neuroinflammation in health and disease. Int. Neurourol. J. 2019;23:S82&#x2013;S92. doi: 10.5213/inj.1938214.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.5213/inj.1938214.107</ArticleId><ArticleId IdType="pmc">PMC6905205</ArticleId><ArticleId IdType="pubmed">31795607</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Zhu J, Liu XD, Luo MY, Xu NJ. Roles of physical exercise in neurodegeneration: reversal of epigenetic clock. Transl. Neurodegener. 2021;10:30. doi: 10.1186/s40035-021-00254-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00254-1</ArticleId><ArticleId IdType="pmc">PMC8361623</ArticleId><ArticleId IdType="pubmed">34389067</ArticleId></ArticleIdList></Reference><Reference><Citation>De Miguel Z, et al. Exercise plasma boosts memory and dampens brain inflammation via clusterin. Nature. 2021;600:494&#x2013;499. doi: 10.1038/s41586-021-04183-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04183-x</ArticleId><ArticleId IdType="pmc">PMC9721468</ArticleId><ArticleId IdType="pubmed">34880498</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkiewicz MA, et al. Blood-brain barrier permeability and physical exercise. J. Neuroinflamm. 2019;16:15. doi: 10.1186/s12974-019-1403-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1403-x</ArticleId><ArticleId IdType="pmc">PMC6345022</ArticleId><ArticleId IdType="pubmed">30678702</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata F, Nakagawa S, Matsumoto J, Dohgu S. Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction. Front. Cell. Neurosci. 2021;15:661838. doi: 10.3389/fncel.2021.661838.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.661838</ArticleId><ArticleId IdType="pmc">PMC8475767</ArticleId><ArticleId IdType="pubmed">34588955</ArticleId></ArticleIdList></Reference><Reference><Citation>Solar P, Zamani A, Kubickova L, Dubovy P, Joukal M. Choroid plexus and the blood-cerebrospinal fluid barrier in disease. Fluids Barriers CNS. 2020;17:35. doi: 10.1186/s12987-020-00196-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-020-00196-2</ArticleId><ArticleId IdType="pmc">PMC7201396</ArticleId><ArticleId IdType="pubmed">32375819</ArticleId></ArticleIdList></Reference><Reference><Citation>Procter TV, Williams A, Montagne A. Interplay between brain pericytes and endothelial cells in dementia. Am. J. Pathol. 2021;191:1917&#x2013;1931. doi: 10.1016/j.ajpath.2021.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2021.07.003</ArticleId><ArticleId IdType="pubmed">34329605</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer&#x2019;s Coordinating Centre. Brain. 2013;136:2697&#x2013;2706. doi: 10.1093/brain/awt188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt188</ArticleId><ArticleId IdType="pmc">PMC3858112</ArticleId><ArticleId IdType="pubmed">23842566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, et al. A human brain vascular atlas reveals diverse mediators of Alzheimer&#x2019;s risk. Nature. 2022;603:885&#x2013;892. doi: 10.1038/s41586-021-04369-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04369-3</ArticleId><ArticleId IdType="pmc">PMC9635042</ArticleId><ArticleId IdType="pubmed">35165441</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gool B, et al. LRP1 has a predominant role in production over clearance of abeta in a mouse model of Alzheimer&#x2019;s disease. Mol. Neurobiol. 2019;56:7234&#x2013;7245. doi: 10.1007/s12035-019-1594-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1594-2</ArticleId><ArticleId IdType="pmc">PMC6728278</ArticleId><ArticleId IdType="pubmed">31004319</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrano A, et al. ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy. Neurobiol. Aging. 2014;35:565&#x2013;575. doi: 10.1016/j.neurobiolaging.2013.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.015</ArticleId><ArticleId IdType="pubmed">24138987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer&#x2019;s disease. Neurobiol. Dis. 2017;107:41&#x2013;56. doi: 10.1016/j.nbd.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.07.007</ArticleId><ArticleId IdType="pmc">PMC5600438</ArticleId><ArticleId IdType="pubmed">27425887</ArticleId></ArticleIdList></Reference><Reference><Citation>Senatorov, V. V., Jr. et al. Blood-brain barrier dysfunction in aging induces hyperactivation of TGFbeta signaling and chronic yet reversible neural dysfunction. Sci. Transl. Med. 11, eaaw8283 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31801886</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes-Canteli M, Iadecola C. Alzheimer&#x2019;s disease and vascular aging: JACC focus seminar. J. Am. Coll. Cardiol. 2020;75:942&#x2013;951. doi: 10.1016/j.jacc.2019.10.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.10.062</ArticleId><ArticleId IdType="pmc">PMC8046164</ArticleId><ArticleId IdType="pubmed">32130930</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med. 2019;25:270&#x2013;276. doi: 10.1038/s41591-018-0297-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0297-y</ArticleId><ArticleId IdType="pmc">PMC6367058</ArticleId><ArticleId IdType="pubmed">30643288</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, et al. Prenatal disruption of blood-brain barrier formation via cyclooxygenase activation leads to lifelong brain inflammation. Proc. Natl Acad. Sci. USA. 2022;119:e2113310119. doi: 10.1073/pnas.2113310119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2113310119</ArticleId><ArticleId IdType="pmc">PMC9169666</ArticleId><ArticleId IdType="pubmed">35377817</ArticleId></ArticleIdList></Reference><Reference><Citation>Strazielle N, Ghersi-Egea JF. Choroid plexus in the central nervous system: biology and physiopathology. J. Neuropathol. Exp. Neurol. 2000;59:561&#x2013;574. doi: 10.1093/jnen/59.7.561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/59.7.561</ArticleId><ArticleId IdType="pubmed">10901227</ArticleId></ArticleIdList></Reference><Reference><Citation>Giao T, Teixeira T, Almeida MR, Cardoso I. Choroid plexus in Alzheimer&#x2019;s disease-the current state of knowledge. Biomedicines. 2022;10:224. doi: 10.3390/biomedicines10020224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10020224</ArticleId><ArticleId IdType="pmc">PMC8869376</ArticleId><ArticleId IdType="pubmed">35203434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayub M, Jin HK, Bae JS. The blood cerebrospinal fluid barrier orchestrates immunosurveillance, immunoprotection, and immunopathology in the central nervous system. BMB Rep. 2021;54:196&#x2013;202. doi: 10.5483/BMBRep.2021.54.4.205.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2021.54.4.205</ArticleId><ArticleId IdType="pmc">PMC8093941</ArticleId><ArticleId IdType="pubmed">33298242</ArticleId></ArticleIdList></Reference><Reference><Citation>Shechter R, et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity. 2013;38:555&#x2013;569. doi: 10.1016/j.immuni.2013.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.02.012</ArticleId><ArticleId IdType="pmc">PMC4115271</ArticleId><ArticleId IdType="pubmed">23477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunis G, et al. IFN-gamma-dependent activation of the brain&#x2019;s choroid plexus for CNS immune surveillance and repair. Brain. 2013;136:3427&#x2013;3440. doi: 10.1093/brain/awt259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt259</ArticleId><ArticleId IdType="pubmed">24088808</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science. 2014;346:89&#x2013;93. doi: 10.1126/science.1252945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1252945</ArticleId><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunis G, Baruch K, Miller O, Schwartz M. Immunization with a myelin-derived antigen activates the brain&#x2019;s choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS. J. Neurosci. 2015;35:6381&#x2013;6393. doi: 10.1523/JNEUROSCI.3644-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3644-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605216</ArticleId><ArticleId IdType="pubmed">25904790</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer&#x2019;s disease pathology. Nat. Commun. 2015;6:7967. doi: 10.1038/ncomms8967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8967</ArticleId><ArticleId IdType="pmc">PMC4557123</ArticleId><ArticleId IdType="pubmed">26284939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesquita SD, et al. The choroid plexus transcriptome reveals changes in type I and II interferon responses in a mouse model of Alzheimer&#x2019;s disease. Brain. Behav. Immun. 2015;49:280&#x2013;292. doi: 10.1016/j.bbi.2015.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.06.008</ArticleId><ArticleId IdType="pubmed">26092102</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer&#x2019;s disease. Nat. Med. 2016;22:135&#x2013;137. doi: 10.1038/nm.4022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4022</ArticleId><ArticleId IdType="pubmed">26779813</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, Kertser A, Porat Z, Schwartz M. Cerebral nitric oxide represses choroid plexus NFkappaB-dependent gateway activity for leukocyte trafficking. EMBO J. 2015;34:1816&#x2013;1828. doi: 10.15252/embj.201591468.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201591468</ArticleId><ArticleId IdType="pmc">PMC4516433</ArticleId><ArticleId IdType="pubmed">25940071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer&#x2019;s disease progression. Cell Res. 2019;29:787&#x2013;803. doi: 10.1038/s41422-019-0216-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-019-0216-x</ArticleId><ArticleId IdType="pmc">PMC6796854</ArticleId><ArticleId IdType="pubmed">31488882</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominy SS, et al. Porphyromonas gingivalis in Alzheimer&#x2019;s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 2019;5:eaau3333. doi: 10.1126/sciadv.aau3333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aau3333</ArticleId><ArticleId IdType="pmc">PMC6357742</ArticleId><ArticleId IdType="pubmed">30746447</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, et al. Risk prediction of late-onset Alzheimer&#x2019;s disease implies an oligogenic architecture. Nat. Commun. 2020;11:4799. doi: 10.1038/s41467-020-18534-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18534-1</ArticleId><ArticleId IdType="pmc">PMC7511365</ArticleId><ArticleId IdType="pubmed">32968074</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer&#x2019;s disease revisited. Alzheimers Dement. 2016;12:733&#x2013;748. doi: 10.1016/j.jalz.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.012</ArticleId><ArticleId IdType="pubmed">27016693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges AK, Piers TM, Collier D, Cousins O, Pocock JM. Pathways linking Alzheimer&#x2019;s disease risk genes expressed highly in microglia. Neuroimmunol. Neuroinflamm. 2021;8:245.</Citation></Reference><Reference><Citation>Bellenguez C, et al. New insights into the genetic etiology of Alzheimer&#x2019;s disease and related dementias. Nat. Genet. 2022;54:412&#x2013;436. doi: 10.1038/s41588-022-01024-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01024-z</ArticleId><ArticleId IdType="pmc">PMC9005347</ArticleId><ArticleId IdType="pubmed">35379992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashioka S, Inoue K, Takeshita H, Inagaki M. Do Alzheimer&#x2019;s disease risk gene products actually act in microglia? Front. Aging Neurosci. 2020;12:589196. doi: 10.3389/fnagi.2020.589196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.589196</ArticleId><ArticleId IdType="pmc">PMC7744292</ArticleId><ArticleId IdType="pubmed">33343331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch JR, et al. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann. Neurol. 2002;51:113&#x2013;117. doi: 10.1002/ana.10098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10098</ArticleId><ArticleId IdType="pubmed">11782990</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, et al. Apolipoprotein E knockout induced inflammatory responses related to microglia in neonatal mice brain via astrocytes. Int. J. Clin. Exp. Med. 2015;8:737&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358506</ArticleId><ArticleId IdType="pubmed">25785051</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami M, Ushio Y, Morino Y, Ohta T, Matsukado Y. Immunohistochemical localization of apolipoprotein E in human glial neoplasms. J. Clin. Invest. 1988;82:177&#x2013;188. doi: 10.1172/JCI113568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI113568</ArticleId><ArticleId IdType="pmc">PMC303492</ArticleId><ArticleId IdType="pubmed">3392206</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS, et al. Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J. Exp. Med. 2018;215:2235&#x2013;2245. doi: 10.1084/jem.20180653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180653</ArticleId><ArticleId IdType="pmc">PMC6122978</ArticleId><ArticleId IdType="pubmed">30082275</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 2019;15:501&#x2013;518. doi: 10.1038/s41582-019-0228-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0228-7</ArticleId><ArticleId IdType="pmc">PMC7055192</ArticleId><ArticleId IdType="pubmed">31367008</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013;9:106&#x2013;118. doi: 10.1038/nrneurol.2012.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.263</ArticleId><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, et al. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol. 2017;74:1178&#x2013;1189. doi: 10.1001/jamaneurol.2017.2188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2188</ArticleId><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao YC, Ho PC, Tu YK, Jou IM, Tsai KJ. Lipids and Alzheimer&#x2019;s disease. Int. J. Mol. Sci. 2020;21:1505. doi: 10.3390/ijms21041505.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21041505</ArticleId><ArticleId IdType="pmc">PMC7073164</ArticleId><ArticleId IdType="pubmed">32098382</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW. The role of APOE on lipid homeostasis and inflammation in normal brains. J. Lipid Res. 2017;58:1493&#x2013;1499. doi: 10.1194/jlr.R075408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R075408</ArticleId><ArticleId IdType="pmc">PMC5538293</ArticleId><ArticleId IdType="pubmed">28258087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V, Kim SH, Bishayee K. Dysfunctional glucose metabolism in Alzheimer&#x2019;s disease onset and potential pharmacological interventions. Int. J. Mol. Sci. 2022;23:9540. doi: 10.3390/ijms23179540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23179540</ArticleId><ArticleId IdType="pmc">PMC9455726</ArticleId><ArticleId IdType="pubmed">36076944</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron. 2017;96:115&#x2013;129.e115. doi: 10.1016/j.neuron.2017.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.09.003</ArticleId><ArticleId IdType="pmc">PMC5621659</ArticleId><ArticleId IdType="pubmed">28957663</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Zhang X, Zhao L. Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer&#x2019;s disease risk reduction and early intervention. J. Neurosci. 2018;38:6665&#x2013;6681. doi: 10.1523/JNEUROSCI.2262-17.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2262-17.2018</ArticleId><ArticleId IdType="pmc">PMC6067075</ArticleId><ArticleId IdType="pubmed">29967007</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeney JT, Ibrahimi S, Zhao L. Human ApoE isoforms differentially modulate glucose and amyloid metabolic pathways in female brain: evidence of the mechanism of neuroprotection by ApoE2 and implications for Alzheimer&#x2019;s disease prevention and early intervention. J. Alzheimer&#x2019;s Dis. 2015;48:411&#x2013;424. doi: 10.3233/JAD-150348.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150348</ArticleId><ArticleId IdType="pmc">PMC5485924</ArticleId><ArticleId IdType="pubmed">26402005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebright B, et al. Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer&#x2019;s dementia. Alzheimers Res. Ther. 2022;14:152. doi: 10.1186/s13195-022-01084-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-022-01084-7</ArticleId><ArticleId IdType="pmc">PMC9552454</ArticleId><ArticleId IdType="pubmed">36217192</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527. doi: 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YT, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer&#x2019;s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141&#x2013;1154.e1147. doi: 10.1016/j.neuron.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.008</ArticleId><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Teter B, LaDu MJ, Sullivan PM, Frautschy SA, Cole GM. Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain. Neuroreport. 2016;27:791&#x2013;795. doi: 10.1097/WNR.0000000000000608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0000000000000608</ArticleId><ArticleId IdType="pmc">PMC5042345</ArticleId><ArticleId IdType="pubmed">27281274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J. Biol. Chem. 2008;283:31315&#x2013;31322. doi: 10.1074/jbc.M805371200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805371200</ArticleId><ArticleId IdType="pmc">PMC2581572</ArticleId><ArticleId IdType="pubmed">18801740</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, et al. APOE4 drives inflammation in human astrocytes via TAGLN3 repression and NF-kappaB activation. Cell Rep. 2022;40:111200. doi: 10.1016/j.celrep.2022.111200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111200</ArticleId><ArticleId IdType="pubmed">35977506</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2) J. Biol. Chem. 2015;290:26043&#x2013;26050. doi: 10.1074/jbc.M115.679043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.679043</ArticleId><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;581.e569. doi: 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512&#x2013;516. doi: 10.1038/nature11087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11087</ArticleId><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557&#x2013;561. doi: 10.1038/nature09522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09522</ArticleId><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71&#x2013;76. doi: 10.1038/s41586-020-2247-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2247-3</ArticleId><ArticleId IdType="pmc">PMC7250000</ArticleId><ArticleId IdType="pubmed">32376954</ArticleId></ArticleIdList></Reference><Reference><Citation>Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer&#x2019;s disease. BMC Med. 2019;17:64. doi: 10.1186/s12916-019-1299-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1299-4</ArticleId><ArticleId IdType="pmc">PMC6425600</ArticleId><ArticleId IdType="pubmed">30890171</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona S, et al. The role of TREM2 in Alzheimer&#x2019;s disease and other neurodegenerative disorders. Lancet Neurol. 2018;17:721&#x2013;730. doi: 10.1016/S1474-4422(18)30232-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30232-1</ArticleId><ArticleId IdType="pubmed">30033062</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu H, et al. TREM2: keeping pace with immune checkpoint inhibitors in cancer immunotherapy. Front. Immunol. 2021;12:716710. doi: 10.3389/fimmu.2021.716710.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.716710</ArticleId><ArticleId IdType="pmc">PMC8446424</ArticleId><ArticleId IdType="pubmed">34539652</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M. DAP12 signaling: from immune cells to bone modeling and brain myelination. J. Clin. Invest. 2003;111:313&#x2013;314. doi: 10.1172/JCI17745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI17745</ArticleId><ArticleId IdType="pmc">PMC151875</ArticleId><ArticleId IdType="pubmed">12569153</ArticleId></ArticleIdList></Reference><Reference><Citation>Samanci B, et al. TREM2 variants as a possible cause of frontotemporal dementia with distinct neuroimaging features. Eur. J. Neurol. 2021;28:2603&#x2013;2613. doi: 10.1111/ene.14908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14908</ArticleId><ArticleId IdType="pubmed">33969597</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, et al. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Hum. Mol. Genet. 2014;23:5838&#x2013;5846. doi: 10.1093/hmg/ddu277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu277</ArticleId><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober DL, et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife. 2016;5:e20391. doi: 10.7554/eLife.20391.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.20391</ArticleId><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Wang X, He P. The most prevalent rare coding variants of TREM2 conferring risk of Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Exp. Ther. Med. 2021;21:347. doi: 10.3892/etm.2021.9778.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.9778</ArticleId><ArticleId IdType="pmc">PMC7903442</ArticleId><ArticleId IdType="pubmed">33732320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 2014;6:243ra286. doi: 10.1126/scitranslmed.3009093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009093</ArticleId><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Ji IJ, Kim DH, An HJ, Yoon SY. The Alzheimer&#x2019;s disease-associated R47H variant of TREM2 has an altered glycosylation pattern and protein stability. Front. Neurosci. 2016;10:618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241589</ArticleId><ArticleId IdType="pubmed">28149270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudom A, et al. Molecular basis for the loss-of-function effects of the Alzheimer&#x2019;s disease-associated R47H variant of the immune receptor TREM2. J. Biol. Chem. 2018;293:12634&#x2013;12646. doi: 10.1074/jbc.RA118.002352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.002352</ArticleId><ArticleId IdType="pmc">PMC6093241</ArticleId><ArticleId IdType="pubmed">29794134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, et al. Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer&#x2019;s disease brains. Mol. Neurodegener. 2016;11:72. doi: 10.1186/s13024-016-0137-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0137-9</ArticleId><ArticleId IdType="pmc">PMC5124229</ArticleId><ArticleId IdType="pubmed">27887626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071. doi: 10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med. 2018;215:745&#x2013;760. doi: 10.1084/jem.20171529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171529</ArticleId><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 2019;22:1217&#x2013;1222. doi: 10.1038/s41593-019-0433-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0433-0</ArticleId><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724&#x2013;739. doi: 10.1016/j.neuron.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer&#x2019;s disease. Neuron. 2013;78:256&#x2013;268. doi: 10.1016/j.neuron.2013.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.026</ArticleId><ArticleId IdType="pmc">PMC3664945</ArticleId><ArticleId IdType="pubmed">23562540</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129:3035&#x2013;3041. doi: 10.1093/brain/awl269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl269</ArticleId><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer&#x2019;s disease. Nat. Commun. 2020;11:5370. doi: 10.1038/s41467-020-19227-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19227-5</ArticleId><ArticleId IdType="pmc">PMC7584603</ArticleId><ArticleId IdType="pubmed">33097708</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M, et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J. Clin. Invest. 2020;130:4954&#x2013;4968. doi: 10.1172/JCI138179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138179</ArticleId><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed FA, et al. AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation. Sci. Transl. Med. 2021;13:eabe3947. doi: 10.1126/scitranslmed.abe3947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abe3947</ArticleId><ArticleId IdType="pmc">PMC9345574</ArticleId><ArticleId IdType="pubmed">34851693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren S, et al. Microglia TREM2(R47H) Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF-alpha levels. Elife. 2020;9:e57513. doi: 10.7554/eLife.57513.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.57513</ArticleId><ArticleId IdType="pmc">PMC7338048</ArticleId><ArticleId IdType="pubmed">32579116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren S, et al. TNF-alpha-mediated reduction in inhibitory neurotransmission precedes sporadic Alzheimer&#x2019;s disease pathology in young Trem2(R47H) rats. J. Biol. Chem. 2021;296:100089. doi: 10.1074/jbc.RA120.016395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.016395</ArticleId><ArticleId IdType="pmc">PMC7949092</ArticleId><ArticleId IdType="pubmed">33434745</ArticleId></ArticleIdList></Reference><Reference><Citation>Korvatska O, et al. Triggering receptor expressed on myeloid cell 2 R47H exacerbates immune response in Alzheimer&#x2019;s disease brain. Front. Immunol. 2020;11:559342. doi: 10.3389/fimmu.2020.559342.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.559342</ArticleId><ArticleId IdType="pmc">PMC7546799</ArticleId><ArticleId IdType="pubmed">33101276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober DL, Brett TJ. TREM2-ligand interactions in health and disease. J. Mol. Biol. 2017;429:1607&#x2013;1629. doi: 10.1016/j.jmb.2017.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2017.04.004</ArticleId><ArticleId IdType="pmc">PMC5485854</ArticleId><ArticleId IdType="pubmed">28432014</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181:1207&#x2013;1217. doi: 10.1016/j.cell.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.003</ArticleId><ArticleId IdType="pubmed">32531244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabori M, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J. Neurosci. 2015;35:3384&#x2013;3396. doi: 10.1523/JNEUROSCI.2620-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2620-14.2015</ArticleId><ArticleId IdType="pmc">PMC4339351</ArticleId><ArticleId IdType="pubmed">25716838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 2020;26:131&#x2013;142. doi: 10.1038/s41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 2019;22:2087&#x2013;2097. doi: 10.1038/s41593-019-0539-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, et al. TREM2 protein expression changes correlate with Alzheimer&#x2019;s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol. 2015;25:469&#x2013;480. doi: 10.1111/bpa.12190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12190</ArticleId><ArticleId IdType="pmc">PMC4427527</ArticleId><ArticleId IdType="pubmed">25186950</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, et al. Untangling the brain&#x2019;s neuroinflammatory and neurodegenerative transcriptional responses. Nat. Commun. 2016;7:11295. doi: 10.1038/ncomms11295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11295</ArticleId><ArticleId IdType="pmc">PMC4844685</ArticleId><ArticleId IdType="pubmed">27097852</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, et al. Immune hyperreactivity of Abeta plaque-associated microglia in Alzheimer&#x2019;s disease. Neurobiol. Aging. 2017;55:115&#x2013;122. doi: 10.1016/j.neurobiolaging.2017.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.03.021</ArticleId><ArticleId IdType="pubmed">28434692</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J, et al. A survey of TREM2 antibodies reveals neuronal but not microglial staining in formalin-fixed paraffin-embedded postmortem Alzheimer&#x2019;s brain tissues. Alzheimers Res. Ther. 2013;5:30. doi: 10.1186/alzrt184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt184</ArticleId><ArticleId IdType="pmc">PMC3978710</ArticleId><ArticleId IdType="pubmed">23830013</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahrenhold M, et al. TREM2 expression in the human brain: a marker of monocyte recruitment? Brain Pathol. 2018;28:595&#x2013;602. doi: 10.1111/bpa.12564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12564</ArticleId><ArticleId IdType="pmc">PMC6221091</ArticleId><ArticleId IdType="pubmed">28987033</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue F, Du H. TREM2 mediates microglial anti-inflammatory activations in Alzheimer&#x2019;s disease: lessons learned from transcriptomics. Cells. 2021;10:321. doi: 10.3390/cells10020321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020321</ArticleId><ArticleId IdType="pmc">PMC7913972</ArticleId><ArticleId IdType="pubmed">33557250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron. 2018;97:1023&#x2013;1031.e1027. doi: 10.1016/j.neuron.2018.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.01.031</ArticleId><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, von Saucken VE, Landreth GE. TREM2 in neurodegenerative diseases. Mol. Neurodegener. 2017;12:56. doi: 10.1186/s13024-017-0197-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0197-5</ArticleId><ArticleId IdType="pmc">PMC5541421</ArticleId><ArticleId IdType="pubmed">28768545</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e1217. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 2016;213:667&#x2013;675. doi: 10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer&#x2019;s disease. Neuropsychopharmacology. 2014;39:2949&#x2013;2962. doi: 10.1038/npp.2014.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2014.164</ArticleId><ArticleId IdType="pmc">PMC4229581</ArticleId><ArticleId IdType="pubmed">25047746</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, et al. TREM2 overexpression has no improvement on neuropathology and cognitive impairment in aging APPswe/PS1dE9 mice. Mol. Neurobiol. 2017;54:855&#x2013;865. doi: 10.1007/s12035-016-9704-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9704-x</ArticleId><ArticleId IdType="pubmed">26780455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, et al. Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer&#x2019;s disease models. Neuron. 2018;97:1032&#x2013;1048.e1035. doi: 10.1016/j.neuron.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.002</ArticleId><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 2017;37:637&#x2013;647. doi: 10.1523/JNEUROSCI.2110-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2110-16.2016</ArticleId><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med. 2015;212:287&#x2013;295. doi: 10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller SM, et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol. Neurodegener. 2017;12:74. doi: 10.1186/s13024-017-0216-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0216-6</ArticleId><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl Acad. Sci. USA. 2017;114:11524&#x2013;11529. doi: 10.1073/pnas.1710311114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed FA, et al. Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc. Natl Acad. Sci. USA. 2018;115:10172&#x2013;10177. doi: 10.1073/pnas.1811411115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1811411115</ArticleId><ArticleId IdType="pmc">PMC6176614</ArticleId><ArticleId IdType="pubmed">30232263</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta-amyloid pathology. Neuron. 2021;109:1283&#x2013;1301.e1286. doi: 10.1016/j.neuron.2021.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.02.010</ArticleId><ArticleId IdType="pubmed">33675684</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N, Lewis CA, Ulrich JD, Holtzman DM. Chronic TREM2 activation exacerbates Abeta-associated tau seeding and spreading. J. Exp. Med. 2023;220:e20220654. doi: 10.1084/jem.20220654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220654</ArticleId><ArticleId IdType="pmc">PMC9559604</ArticleId><ArticleId IdType="pubmed">36219197</ArticleId></ArticleIdList></Reference><Reference><Citation>Belsare KD, et al. Soluble TREM2 inhibits secondary nucleation of Abeta fibrillization and enhances cellular uptake of fibrillar Abeta. Proc. Natl. Acad. Sci. USA. 2022;119:e2114486119. doi: 10.1073/pnas.2114486119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2114486119</ArticleId><ArticleId IdType="pmc">PMC8812518</ArticleId><ArticleId IdType="pubmed">35082148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer&#x2019;s disease. Sci. Transl. Med. 2019;11:eaav6221. doi: 10.1126/scitranslmed.aav6221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav6221</ArticleId><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer&#x2019;s disease model. Nat. Commun. 2019;10:1365. doi: 10.1038/s41467-019-09118-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09118-9</ArticleId><ArticleId IdType="pmc">PMC6433910</ArticleId><ArticleId IdType="pubmed">30911003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J. Exp. Med. 2017;214:597&#x2013;607. doi: 10.1084/jem.20160844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160844</ArticleId><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="pubmed">28209725</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi H, Kiyama H. Microglial TREM2/DAP12 Signaling: a double-edged sword in neural diseases. Front. Cell. Neurosci. 2018;12:206. doi: 10.3389/fncel.2018.00206.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00206</ArticleId><ArticleId IdType="pmc">PMC6087757</ArticleId><ArticleId IdType="pubmed">30127720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman JA, et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J. Immunol. 2006;177:2051&#x2013;2055. doi: 10.4049/jimmunol.177.4.2051.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.4.2051</ArticleId><ArticleId IdType="pubmed">16887962</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, et al. Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 2006;177:3520&#x2013;3524. doi: 10.4049/jimmunol.177.6.3520.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.6.3520</ArticleId><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. TREM2/DAP12 complex regulates inflammatory responses in microglia via the JNK signaling pathway. Front. Aging Neurosci. 2017;9:204. doi: 10.3389/fnagi.2017.00204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00204</ArticleId><ArticleId IdType="pmc">PMC5478682</ArticleId><ArticleId IdType="pubmed">28680398</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Colonna M. Activating and inhibitory functions of DAP12. Nat. Rev. Immunol. 2007;7:155&#x2013;161. doi: 10.1038/nri2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2014</ArticleId><ArticleId IdType="pubmed">17220916</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine CS, et al. Astrocytic interleukin-3 programs microglia and limits Alzheimer&#x2019;s disease. Nature. 2021;595:701&#x2013;706. doi: 10.1038/s41586-021-03734-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03734-6</ArticleId><ArticleId IdType="pmc">PMC8934148</ArticleId><ArticleId IdType="pubmed">34262178</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, et al. TREM2 deficiency aggravates alpha-synuclein-induced neurodegeneration and neuroinflammation in Parkinson&#x2019;s disease models. FASEB J. 2019;33:12164&#x2013;12174. doi: 10.1096/fj.201900992R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201900992R</ArticleId><ArticleId IdType="pmc">PMC6902667</ArticleId><ArticleId IdType="pubmed">31370707</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, et al. TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration. Nat. Neurosci. 2022;25:26&#x2013;38. doi: 10.1038/s41593-021-00975-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00975-6</ArticleId><ArticleId IdType="pmc">PMC8741737</ArticleId><ArticleId IdType="pubmed">34916658</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, Goate AM. Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 2017;12:43. doi: 10.1186/s13024-017-0184-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0184-x</ArticleId><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Tanzi RE. The role of innate immune genes in Alzheimer&#x2019;s disease. Curr. Opin. Neurol. 2021;34:228&#x2013;236. doi: 10.1097/WCO.0000000000000911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000911</ArticleId><ArticleId IdType="pmc">PMC7954128</ArticleId><ArticleId IdType="pubmed">33560670</ArticleId></ArticleIdList></Reference><Reference><Citation>Witoelar A, et al. Genome-wide pleiotropy between parkinson disease and autoimmune diseases. JAMA Neurol. 2017;74:780&#x2013;792. doi: 10.1001/jamaneurol.2017.0469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0469</ArticleId><ArticleId IdType="pmc">PMC5710535</ArticleId><ArticleId IdType="pubmed">28586827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui KY, et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn&#x2019;s disease and Parkinson&#x2019;s disease. Sci. Transl. Med. 2018;10:eaai7795. doi: 10.1126/scitranslmed.aai7795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7795</ArticleId><ArticleId IdType="pmc">PMC6028002</ArticleId><ArticleId IdType="pubmed">29321258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091&#x2013;1102. doi: 10.1016/S1474-4422(19)30320-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30320-5</ArticleId><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: mendelian versus non-mendelian inheritance. J. Neurochem. 2016;139:59&#x2013;74. doi: 10.1111/jnc.13593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13593</ArticleId><ArticleId IdType="pmc">PMC5155439</ArticleId><ArticleId IdType="pubmed">27090875</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusen AF, Hatton SL, Rani R, Pandey MK. Genetic defects and pro-inflammatory cytokines in Parkinson&#x2019;s disease. Front. Neurol. 2021;12:636139. doi: 10.3389/fneur.2021.636139.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.636139</ArticleId><ArticleId IdType="pmc">PMC8259624</ArticleId><ArticleId IdType="pubmed">34239490</ArticleId></ArticleIdList></Reference><Reference><Citation>Rideout HJ, Re DB. LRRK2 and the &#x201c;LRRKtosome&#x201d; at the crossroads of programmed cell death: clues from RIP kinase relatives. Adv. Neurobiol. 2017;14:193&#x2013;208. doi: 10.1007/978-3-319-49969-7_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-49969-7_10</ArticleId><ArticleId IdType="pubmed">28353285</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fonzo A, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson&#x2019;s disease. Lancet. 2005;365:412&#x2013;415. doi: 10.1016/S0140-6736(05)17829-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)17829-5</ArticleId><ArticleId IdType="pubmed">15680456</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006;9:1231&#x2013;1233. doi: 10.1038/nn1776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1776</ArticleId><ArticleId IdType="pubmed">16980962</ArticleId></ArticleIdList></Reference><Reference><Citation>West AB, et al. Parkinson&#x2019;s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA. 2005;102:16842&#x2013;16847. doi: 10.1073/pnas.0507360102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0507360102</ArticleId><ArticleId IdType="pmc">PMC1283829</ArticleId><ArticleId IdType="pubmed">16269541</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzamko N, Rowe DB, Halliday GM. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. Mov. Disord. 2016;31:889&#x2013;897. doi: 10.1002/mds.26529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26529</ArticleId><ArticleId IdType="pubmed">26917005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DA, et al. LRRK2 levels in immune cells are increased in Parkinson&#x2019;s disease. NPJ Parkinsons Dis. 2017;3:11. doi: 10.1038/s41531-017-0010-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-017-0010-8</ArticleId><ArticleId IdType="pmc">PMC5459798</ArticleId><ArticleId IdType="pubmed">28649611</ArticleId></ArticleIdList></Reference><Reference><Citation>Shutinoski B, et al. Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Sci. Transl. Med. 2019;11:eaas9292. doi: 10.1126/scitranslmed.aas9292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aas9292</ArticleId><ArticleId IdType="pubmed">31554740</ArticleId></ArticleIdList></Reference><Reference><Citation>Atashrazm F, et al. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson&#x2019;s disease patients. Mov. Disord. 2019;34:406&#x2013;415. doi: 10.1002/mds.27601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27601</ArticleId><ArticleId IdType="pubmed">30597610</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicker LM, et al. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc. Natl Acad. Sci. USA. 2012;109:18054&#x2013;18059. doi: 10.1073/pnas.1207889109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1207889109</ArticleId><ArticleId IdType="pmc">PMC3497826</ArticleId><ArticleId IdType="pubmed">23071332</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicker LM, et al. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells. 2014;32:2338&#x2013;2349. doi: 10.1002/stem.1732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1732</ArticleId><ArticleId IdType="pmc">PMC4138241</ArticleId><ArticleId IdType="pubmed">24801745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahine LM, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013;70:852&#x2013;858. doi: 10.1001/jamaneurol.2013.1274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.1274</ArticleId><ArticleId IdType="pmc">PMC3762458</ArticleId><ArticleId IdType="pubmed">23699752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizukami H, et al. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J. Clin. Invest. 2002;109:1215&#x2013;1221. doi: 10.1172/JCI0214530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0214530</ArticleId><ArticleId IdType="pmc">PMC150961</ArticleId><ArticleId IdType="pubmed">11994410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira M, Massano J. An updated review of Parkinson&#x2019;s disease genetics and clinicopathological correlations. Acta Neurol. Scand. 2017;135:273&#x2013;284. doi: 10.1111/ane.12616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12616</ArticleId><ArticleId IdType="pubmed">27273099</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. Trends Neurosci. 2014;37:315&#x2013;324. doi: 10.1016/j.tins.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4075431</ArticleId><ArticleId IdType="pubmed">24735649</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliter DA, et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018;561:258&#x2013;262. doi: 10.1038/s41586-018-0448-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0448-9</ArticleId><ArticleId IdType="pmc">PMC7362342</ArticleId><ArticleId IdType="pubmed">30135585</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheoud D, et al. Parkinson&#x2019;s disease-related proteins PINK1 and Parkin repress mitochondrial antigen presentation. Cell. 2016;166:314&#x2013;327. doi: 10.1016/j.cell.2016.05.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.039</ArticleId><ArticleId IdType="pubmed">27345367</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 2005;11:493&#x2013;498. doi: 10.1016/j.parkreldis.2005.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2005.07.005</ArticleId><ArticleId IdType="pubmed">16154792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamais A, Kaganovich A, Harvey K. Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson&#x2019;s disease. Neurobiol. Dis. 2022;169:105721. doi: 10.1016/j.nbd.2022.105721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105721</ArticleId><ArticleId IdType="pubmed">35405260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS genetics: gains, losses, and implications for future therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankovic M, et al. Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:9832. doi: 10.3390/ijms22189832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22189832</ArticleId><ArticleId IdType="pmc">PMC8469731</ArticleId><ArticleId IdType="pubmed">34575995</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravnik-Glavac M, et al. Genetic variability of inflammation and oxidative stress genes affects onset, progression of the disease and survival of patients with amyotrophic lateral sclerosis. Genes (Basel) 2022;13:757. doi: 10.3390/genes13050757.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13050757</ArticleId><ArticleId IdType="pmc">PMC9140599</ArticleId><ArticleId IdType="pubmed">35627142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl. Neurodegener. 2020;9:42. doi: 10.1186/s40035-020-00221-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00221-2</ArticleId><ArticleId IdType="pmc">PMC7689983</ArticleId><ArticleId IdType="pubmed">33239064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V. Toll-like receptors in the pathogenesis of neuroinflammation. J. Neuroimmunol. 2019;332:16&#x2013;30. doi: 10.1016/j.jneuroim.2019.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2019.03.012</ArticleId><ArticleId IdType="pubmed">30928868</ArticleId></ArticleIdList></Reference><Reference><Citation>Sameer AS, Nissar S. Toll-Like Receptors (TLRs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility. Biomed. Res. Int. 2021;2021:1157023. doi: 10.1155/2021/1157023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/1157023</ArticleId><ArticleId IdType="pmc">PMC8452412</ArticleId><ArticleId IdType="pubmed">34552981</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar V, Dey M, Dorn R, Raskin I. MyD88-dependent and independent pathways of Toll-Like Receptors are engaged in biological activity of Triptolide in ligand-stimulated macrophages. BMC Chem. Biol. 2010;10:3. doi: 10.1186/1472-6769-10-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6769-10-3</ArticleId><ArticleId IdType="pmc">PMC2873377</ArticleId><ArticleId IdType="pubmed">20385024</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang W, Chao ZY, Feng DY. Role of Toll-like receptor/MYD88 signaling in neurodegenerative diseases. Rev. Neurosci. 2015;26:407&#x2013;414. doi: 10.1515/revneuro-2014-0067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2014-0067</ArticleId><ArticleId IdType="pubmed">25870959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Chen J, Chu F, Zhu J, Jin T. Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis. Front. Mol. Neurosci. 2019;12:314. doi: 10.3389/fnmol.2019.00314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00314</ArticleId><ArticleId IdType="pmc">PMC6965019</ArticleId><ArticleId IdType="pubmed">31998072</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhikarla SV, et al. TLR-mediated signal transduction and neurodegenerative disorders. Brain Sci. 2021;11:1373. doi: 10.3390/brainsci11111373.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11111373</ArticleId><ArticleId IdType="pmc">PMC8615980</ArticleId><ArticleId IdType="pubmed">34827372</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiebich BL, Batista CRA, Saliba SW, Yousif NM, de Oliveira ACP. Role of microglia TLRs in neurodegeneration. Front. Cell. Neurosci. 2018;12:329. doi: 10.3389/fncel.2018.00329.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00329</ArticleId><ArticleId IdType="pmc">PMC6176466</ArticleId><ArticleId IdType="pubmed">30333729</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S, Copanaki E, Burbach GJ, Muller UC, Deller T. Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice. Neurosci. Lett. 2009;453:41&#x2013;44. doi: 10.1016/j.neulet.2009.01.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2009.01.075</ArticleId><ArticleId IdType="pubmed">19429012</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. TLR2 is a primary receptor for Alzheimer&#x2019;s amyloid beta peptide to trigger neuroinflammatory activation. J. Immunol. 2012;188:1098&#x2013;1107. doi: 10.4049/jimmunol.1101121.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101121</ArticleId><ArticleId IdType="pubmed">22198949</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald CL, et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer&#x2019;s disease. Brain. Behav. Immun. 2016;58:191&#x2013;200. doi: 10.1016/j.bbi.2016.07.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.07.143</ArticleId><ArticleId IdType="pubmed">27422717</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangasamy SB, et al. Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer&#x2019;s pathology. J. Clin. Invest. 2018;128:4297&#x2013;4312. doi: 10.1172/JCI96209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI96209</ArticleId><ArticleId IdType="pmc">PMC6159992</ArticleId><ArticleId IdType="pubmed">29990310</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollmar P, et al. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. J. Immunol. 2010;185:6338&#x2013;6347. doi: 10.4049/jimmunol.1001765.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001765</ArticleId><ArticleId IdType="pubmed">20943998</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, et al. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J. Biol. Chem. 2006;281:3651&#x2013;3659. doi: 10.1074/jbc.M508125200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508125200</ArticleId><ArticleId IdType="pubmed">16339765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, et al. Genomic deletion of TLR2 induces aggravated white matter damage and deteriorated neurobehavioral functions in mouse models of Alzheimer&#x2019;s disease. Aging (Albany N. Y.) 2019;11:7257&#x2013;7273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6756907</ArticleId><ArticleId IdType="pubmed">31509519</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourbadie HG, et al. Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer&#x2019;s disease-related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. Neurobiol. Aging. 2018;70:203&#x2013;216. doi: 10.1016/j.neurobiolaging.2018.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.06.020</ArticleId><ArticleId IdType="pubmed">30031930</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouin-Ouellet J, et al. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson&#x2019;s disease. Int. J. Neuropsychopharmacol. 2014;18:pyu103. doi: 10.1093/ijnp/pyu103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyu103</ArticleId><ArticleId IdType="pmc">PMC4438545</ArticleId><ArticleId IdType="pubmed">25522431</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzamko N, et al. Toll-like receptor 2 is increased in neurons in Parkinson&#x2019;s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol. 2017;133:303&#x2013;319. doi: 10.1007/s00401-016-1648-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1648-8</ArticleId><ArticleId IdType="pmc">PMC5250664</ArticleId><ArticleId IdType="pubmed">27888296</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Targeting microglial alpha-synuclein/TLRs/NF-kappaB/NLRP3 inflammasome axis in Parkinson&#x2019;s disease. Front. Immunol. 2021;12:719807. doi: 10.3389/fimmu.2021.719807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.719807</ArticleId><ArticleId IdType="pmc">PMC8531525</ArticleId><ArticleId IdType="pubmed">34691027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Lee HJ, Masliah E, Lee SJ. Non-cell-autonomous neurotoxicity of alpha-synuclein through microglial toll-like receptor 2. Exp. Neurobiol. 2016;25:113&#x2013;119. doi: 10.5607/en.2016.25.3.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2016.25.3.113</ArticleId><ArticleId IdType="pmc">PMC4923355</ArticleId><ArticleId IdType="pubmed">27358579</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Acioglu C, Heary RF, Elkabes S. Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases. Brain Behav. Immun. 2021;91:740&#x2013;755. doi: 10.1016/j.bbi.2020.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.10.007</ArticleId><ArticleId IdType="pmc">PMC7543714</ArticleId><ArticleId IdType="pubmed">33039660</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, et al. Microglial exosomes facilitate alpha-synuclein transmission in Parkinson&#x2019;s disease. Brain. 2020;143:1476&#x2013;1497. doi: 10.1093/brain/awaa090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa090</ArticleId><ArticleId IdType="pmc">PMC7241957</ArticleId><ArticleId IdType="pubmed">32355963</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta D, et al. Selective targeting of the TLR2/MyD88/NF-kappaB pathway reduces alpha-synuclein spreading in vitro and in vivo. Nat. Commun. 2021;12:5382. doi: 10.1038/s41467-021-25767-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25767-1</ArticleId><ArticleId IdType="pmc">PMC8433339</ArticleId><ArticleId IdType="pubmed">34508096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, D&#x2019;Aigle T, Gowing G, Julien JP, Rivest S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2004;24:1340&#x2013;1349. doi: 10.1523/JNEUROSCI.4786-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4786-03.2004</ArticleId><ArticleId IdType="pmc">PMC6730331</ArticleId><ArticleId IdType="pubmed">14960605</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula M, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 2011;179:233&#x2013;243. doi: 10.1016/j.neuroscience.2011.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.02.001</ArticleId><ArticleId IdType="pubmed">21303685</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Hao W, Dawson A, Liu S, Fassbender K. Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J. Biol. Chem. 2009;284:3691&#x2013;3699. doi: 10.1074/jbc.M804446200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M804446200</ArticleId><ArticleId IdType="pubmed">19091752</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, et al. Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by beta-amyloid oligomers in an acute mouse model of Alzheimer&#x2019;s disease. Brain. Behav. Immun. 2017;60:188&#x2013;197. doi: 10.1016/j.bbi.2016.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.10.012</ArticleId><ArticleId IdType="pubmed">27751869</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y, et al. Stimulation of TLR4 attenuates Alzheimer&#x2019;s disease-related symptoms and pathology in Tau-Transgenic mice. J. Immunol. 2016;197:3281&#x2013;3292. doi: 10.4049/jimmunol.1600873.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600873</ArticleId><ArticleId IdType="pubmed">27605009</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellner L, et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia. 2013;61:349&#x2013;360. doi: 10.1002/glia.22437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22437</ArticleId><ArticleId IdType="pmc">PMC3568908</ArticleId><ArticleId IdType="pubmed">23108585</ArticleId></ArticleIdList></Reference><Reference><Citation>Campolo M, et al. TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson&#x2019;s diseases in vivo model. Brain Behav. Immun. 2019;76:236&#x2013;247. doi: 10.1016/j.bbi.2018.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2018.12.003</ArticleId><ArticleId IdType="pubmed">30550933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CD, et al. Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson&#x2019;s disease pathogenesis. Acta Neuropathol. 2019;137:103&#x2013;120. doi: 10.1007/s00401-018-1907-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1907-y</ArticleId><ArticleId IdType="pmc">PMC6338693</ArticleId><ArticleId IdType="pubmed">30225556</ArticleId></ArticleIdList></Reference><Reference><Citation>Venezia S, et al. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal alpha-synucleinopathy. Mol. Neurodegener. 2017;12:52. doi: 10.1186/s13024-017-0195-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0195-7</ArticleId><ArticleId IdType="pmc">PMC5496237</ArticleId><ArticleId IdType="pubmed">28676095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorecki AM, Anyaegbu CC, Anderton RS. TLR2 and TLR4 in Parkinson&#x2019;s disease pathogenesis: the environment takes a toll on the gut. Transl. Neurodegener. 2021;10:47. doi: 10.1186/s40035-021-00271-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00271-0</ArticleId><ArticleId IdType="pmc">PMC8609261</ArticleId><ArticleId IdType="pubmed">34814947</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinotti S, Patrone M, Ranzato E. Emerging roles for HMGB1 protein in immunity, inflammation, and cancer. ImmunoTargets Ther. 2015;4:101&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918250</ArticleId><ArticleId IdType="pubmed">27471716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM. Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J. Neuroinflamm. 2015;12:90. doi: 10.1186/s12974-015-0310-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0310-z</ArticleId><ArticleId IdType="pmc">PMC4431460</ArticleId><ArticleId IdType="pubmed">25962427</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paola M, et al. Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol. Med. 2012;18:971&#x2013;981. doi: 10.2119/molmed.2012.00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2012.00020</ArticleId><ArticleId IdType="pmc">PMC3459480</ArticleId><ArticleId IdType="pubmed">22562723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740&#x2013;745. doi: 10.1038/35047123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35047123</ArticleId><ArticleId IdType="pubmed">11130078</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird AP, Taggart MH, Nicholls RD, Higgs DR. Non-methylated CpG-rich islands at the human alpha-globin locus: implications for evolution of the alpha-globin pseudogene. EMBO J. 1987;6:999&#x2013;1004. doi: 10.1002/j.1460-2075.1987.tb04851.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1987.tb04851.x</ArticleId><ArticleId IdType="pmc">PMC553495</ArticleId><ArticleId IdType="pubmed">3595568</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, et al. CpG methylation patterns of human mitochondrial DNA. Sci. Rep. 2016;6:23421. doi: 10.1038/srep23421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23421</ArticleId><ArticleId IdType="pmc">PMC4800444</ArticleId><ArticleId IdType="pubmed">26996456</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil V, et al. Human mitochondrial DNA is extensively methylated in a non-CpG context. Nucleic Acids Res. 2019;47:10072&#x2013;10085. doi: 10.1093/nar/gkz762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz762</ArticleId><ArticleId IdType="pmc">PMC6821263</ArticleId><ArticleId IdType="pubmed">31665742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008;8:279&#x2013;289. doi: 10.1038/nri2215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2215</ArticleId><ArticleId IdType="pmc">PMC2763408</ArticleId><ArticleId IdType="pubmed">18340345</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros-Bernal F, et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc. Natl Acad. Sci. USA. 2011;108:6632&#x2013;6637. doi: 10.1073/pnas.1017820108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017820108</ArticleId><ArticleId IdType="pmc">PMC3080980</ArticleId><ArticleId IdType="pubmed">21467220</ArticleId></ArticleIdList></Reference><Reference><Citation>Letiembre M, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol. Aging. 2009;30:759&#x2013;768. doi: 10.1016/j.neurobiolaging.2007.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.08.018</ArticleId><ArticleId IdType="pubmed">17905482</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda T, et al. TLR9 signalling in microglia attenuates seizure-induced aberrant neurogenesis in the adult hippocampus. Nat. Commun. 2015;6:6514. doi: 10.1038/ncomms7514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7514</ArticleId><ArticleId IdType="pmc">PMC4366529</ArticleId><ArticleId IdType="pubmed">25751136</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9) FASEB J. 2004;18:412&#x2013;414. doi: 10.1096/fj.03-0670fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.03-0670fje</ArticleId><ArticleId IdType="pubmed">14688201</ArticleId></ArticleIdList></Reference><Reference><Citation>Maatouk L, et al. TLR9 activation via microglial glucocorticoid receptors contributes to degeneration of midbrain dopamine neurons. Nat. Commun. 2018;9:2450. doi: 10.1038/s41467-018-04569-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04569-y</ArticleId><ArticleId IdType="pmc">PMC6015079</ArticleId><ArticleId IdType="pubmed">29934589</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AG, et al. Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer&#x2019;s disease pathology in aged squirrel monkeys. Brain. 2021;144:2146&#x2013;2165. doi: 10.1093/brain/awab129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab129</ArticleId><ArticleId IdType="pmc">PMC8502485</ArticleId><ArticleId IdType="pubmed">34128045</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtzova H, et al. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer&#x2019;s disease-related pathology. J. Neurosci. 2009;29:1846&#x2013;1854. doi: 10.1523/JNEUROSCI.5715-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5715-08.2009</ArticleId><ArticleId IdType="pmc">PMC2699573</ArticleId><ArticleId IdType="pubmed">19211891</ArticleId></ArticleIdList></Reference><Reference><Citation>Juranek J, et al. Role of RAGE in the pathogenesis of neurological disorders. Neurosci. Bull. 2022;38:1248&#x2013;1262. doi: 10.1007/s12264-022-00878-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-022-00878-x</ArticleId><ArticleId IdType="pmc">PMC9554177</ArticleId><ArticleId IdType="pubmed">35729453</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean M, et al. The receptor for advanced glycation end products (RAGE) and DIAPH1: implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system. Neurochem. Int. 2019;126:154&#x2013;164. doi: 10.1016/j.neuint.2019.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2019.03.012</ArticleId><ArticleId IdType="pubmed">30902646</ArticleId></ArticleIdList></Reference><Reference><Citation>Derk J, MacLean M, Juranek J, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and mediation of inflammatory neurodegeneration. J. Alzheimers Dis. Parkinsonism. 2018;8:421. doi: 10.4172/2161-0460.1000421.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2161-0460.1000421</ArticleId><ArticleId IdType="pmc">PMC6293973</ArticleId><ArticleId IdType="pubmed">30560011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpoot S, et al. TIRAP in the mechanism of inflammation. Front. Immunol. 2021;12:697588. doi: 10.3389/fimmu.2021.697588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.697588</ArticleId><ArticleId IdType="pmc">PMC8297548</ArticleId><ArticleId IdType="pubmed">34305934</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr. Diab. Rep. 2014;14:453. doi: 10.1007/s11892-013-0453-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-013-0453-1</ArticleId><ArticleId IdType="pmc">PMC3903318</ArticleId><ArticleId IdType="pubmed">24292971</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheijen J, et al. Analysis of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: presentation of a dietary AGE database. Food Chem. 2016;190:1145&#x2013;1150. doi: 10.1016/j.foodchem.2015.06.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2015.06.049</ArticleId><ArticleId IdType="pubmed">26213088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhla B, et al. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer&#x2019;s disease brains. Neurobiol. Aging. 2007;28:29&#x2013;41. doi: 10.1016/j.neurobiolaging.2005.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.11.007</ArticleId><ArticleId IdType="pubmed">16427160</ArticleId></ArticleIdList></Reference><Reference><Citation>More SS, Vartak AP, Vince R. Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer&#x2019;s disease. ACS Chem. Neurosci. 2013;4:330&#x2013;338. doi: 10.1021/cn3001679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn3001679</ArticleId><ArticleId IdType="pmc">PMC3582295</ArticleId><ArticleId IdType="pubmed">23421684</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer&#x2019;s disease. Nature. 1996;382:685&#x2013;691. doi: 10.1038/382685a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382685a0</ArticleId><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response&#x2013;the evidence mounts. J. Leukoc. Biol. 2009;86:505&#x2013;512. doi: 10.1189/jlb.0409230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0409230</ArticleId><ArticleId IdType="pubmed">19477910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G. Apolipoprotein E and its receptors in Alzheimer&#x2019;s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009;10:333&#x2013;344. doi: 10.1038/nrn2620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2620</ArticleId><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Sbai O, et al. AGE-TXNIP axis drives inflammation in Alzheimer&#x2019;s by targeting Abeta to mitochondria in microglia. Cell Death Dis. 2022;13:302. doi: 10.1038/s41419-022-04758-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04758-0</ArticleId><ArticleId IdType="pmc">PMC8980056</ArticleId><ArticleId IdType="pubmed">35379773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Q, et al. Receptor for advanced glycation end products (RAGE): a pivotal hub in immune diseases. Molecules. 2022;27:4922. doi: 10.3390/molecules27154922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27154922</ArticleId><ArticleId IdType="pmc">PMC9370360</ArticleId><ArticleId IdType="pubmed">35956875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan K, et al. HMGB1 gene silencing inhibits neuroinflammation via down-regulation of NF-kappaB signaling in primary hippocampal neurons induced by Abeta(25-35) Int. Immunopharmacol. 2019;67:294&#x2013;301. doi: 10.1016/j.intimp.2018.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.12.027</ArticleId><ArticleId IdType="pubmed">30572254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathe K, et al. S100B is increased in Parkinson&#x2019;s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain. 2012;135:3336&#x2013;3347. doi: 10.1093/brain/aws250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws250</ArticleId><ArticleId IdType="pmc">PMC3501971</ArticleId><ArticleId IdType="pubmed">23169921</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero E, Vasudevaraju P, Hegde ML, Britton GB, Rao KS. Recent advances in alpha-synuclein functions, advanced glycation, and toxicity: implications for Parkinson&#x2019;s disease. Mol. Neurobiol. 2013;47:525&#x2013;536. doi: 10.1007/s12035-012-8328-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8328-z</ArticleId><ArticleId IdType="pubmed">22923367</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, et al. Association of RAGE gene polymorphisms with sporadic Parkinson&#x2019;s disease in Chinese Han population. Neurosci. Lett. 2014;559:158&#x2013;162. doi: 10.1016/j.neulet.2013.11.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.11.038</ArticleId><ArticleId IdType="pubmed">24304868</ArticleId></ArticleIdList></Reference><Reference><Citation>Teismann P, et al. Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol. Aging. 2012;33:2478&#x2013;2490. doi: 10.1016/j.neurobiolaging.2011.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.12.006</ArticleId><ArticleId IdType="pmc">PMC3712169</ArticleId><ArticleId IdType="pubmed">22227007</ArticleId></ArticleIdList></Reference><Reference><Citation>Juranek JK, et al. Receptor for advanced glycation end products and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2015;9:485. doi: 10.3389/fncel.2015.00485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00485</ArticleId><ArticleId IdType="pmc">PMC4686801</ArticleId><ArticleId IdType="pubmed">26733811</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean M, et al. Microglia RAGE exacerbates the progression of neurodegeneration within the SOD1(G93A) murine model of amyotrophic lateral sclerosis in a sex-dependent manner. J. Neuroinflamm. 2021;18:139. doi: 10.1186/s12974-021-02191-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02191-2</ArticleId><ArticleId IdType="pmc">PMC8207569</ArticleId><ArticleId IdType="pubmed">34130712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, McDonald TS, Fung JNT, Woodruff TM. Absence of receptor for advanced glycation end product (RAGE) reduces inflammation and extends survival in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. Mol. Neurobiol. 2020;57:4143&#x2013;4155. doi: 10.1007/s12035-020-02019-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02019-9</ArticleId><ArticleId IdType="pubmed">32676989</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Killoy KM, Vargas MR, Yamamoto Y, Pehar M. Effects of RAGE inhibition on the progression of the disease in hSOD1(G93A) ALS mice. Pharmacol. Res. Perspect. 2020;8:e00636. doi: 10.1002/prp2.636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.636</ArticleId><ArticleId IdType="pmc">PMC7415959</ArticleId><ArticleId IdType="pubmed">32776498</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H, Agrawal DK. Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors. Drug Dev. Res. 2022;83:1257&#x2013;1269. doi: 10.1002/ddr.21971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21971</ArticleId><ArticleId IdType="pmc">PMC9474610</ArticleId><ArticleId IdType="pubmed">35781678</ArticleId></ArticleIdList></Reference><Reference><Citation>Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol. Med. 2019;11:e10248. doi: 10.15252/emmm.201810248.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201810248</ArticleId><ArticleId IdType="pmc">PMC6554670</ArticleId><ArticleId IdType="pubmed">31015277</ArticleId></ArticleIdList></Reference><Reference><Citation>Piancone F, La Rosa F, Marventano I, Saresella M, Clerici M. The Role of the Inflammasome in Neurodegenerative Diseases. Molecules. 2021;26:953. doi: 10.3390/molecules26040953.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26040953</ArticleId><ArticleId IdType="pmc">PMC7916884</ArticleId><ArticleId IdType="pubmed">33670164</ArticleId></ArticleIdList></Reference><Reference><Citation>Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013;13:397&#x2013;411. doi: 10.1038/nri3452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3452</ArticleId><ArticleId IdType="pmc">PMC3807999</ArticleId><ArticleId IdType="pubmed">23702978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu. Rev. Cell Dev. Biol. 2012;28:137&#x2013;161. doi: 10.1146/annurev-cellbio-101011-155745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-101011-155745</ArticleId><ArticleId IdType="pubmed">22974247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 2019;20:3328. doi: 10.3390/ijms20133328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133328</ArticleId><ArticleId IdType="pmc">PMC6651423</ArticleId><ArticleId IdType="pubmed">31284572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M, Kanneganti TD. Nlrp3: an immune sensor of cellular stress and infection. Int. J. Biochem. Cell Biol. 2010;42:792&#x2013;795. doi: 10.1016/j.biocel.2010.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2010.01.008</ArticleId><ArticleId IdType="pmc">PMC2862759</ArticleId><ArticleId IdType="pubmed">20079456</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008;9:857&#x2013;865. doi: 10.1038/ni.1636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1636</ArticleId><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Parajuli B, et al. Oligomeric amyloid beta induces IL-1beta processing via production of ROS: implication in Alzheimer&#x2019;s disease. Cell Death Dis. 2013;4:e975. doi: 10.1038/cddis.2013.503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.503</ArticleId><ArticleId IdType="pmc">PMC3877570</ArticleId><ArticleId IdType="pubmed">24357806</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678. doi: 10.1038/nature11729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey C, et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice. Brain Behav. Immun. 2017;61:306&#x2013;316. doi: 10.1016/j.bbi.2016.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.12.014</ArticleId><ArticleId IdType="pubmed">28003153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon R, et al. Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 2018;10:eaah4066. doi: 10.1126/scitranslmed.aah4066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah4066</ArticleId><ArticleId IdType="pmc">PMC6483075</ArticleId><ArticleId IdType="pubmed">30381407</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C, et al. Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer&#x2019;s disease. Nature. 2017;552:355&#x2013;361. doi: 10.1038/nature25158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25158</ArticleId><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Codolo G, et al. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8:e55375. doi: 10.1371/journal.pone.0055375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0055375</ArticleId><ArticleId IdType="pmc">PMC3561263</ArticleId><ArticleId IdType="pubmed">23383169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Z, et al. Systemic activation of NLRP3 inflammasome and plasma alpha-synuclein levels are correlated with motor severity and progression in Parkinson&#x2019;s disease. J. Neuroinflamm. 2020;17:11. doi: 10.1186/s12974-019-1670-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1670-6</ArticleId><ArticleId IdType="pmc">PMC6950934</ArticleId><ArticleId IdType="pubmed">31915018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson&#x2019;s disease. Mol. Neurodegener. 2016;11:28. doi: 10.1186/s13024-016-0094-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0094-3</ArticleId><ArticleId IdType="pmc">PMC4833896</ArticleId><ArticleId IdType="pubmed">27084336</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019;26:213&#x2013;228. doi: 10.1038/s41418-018-0124-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0124-5</ArticleId><ArticleId IdType="pmc">PMC6329843</ArticleId><ArticleId IdType="pubmed">29786072</ArticleId></ArticleIdList></Reference><Reference><Citation>Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson&#x2019;s disease. J. Neuroinflamm. 2008;5:8. doi: 10.1186/1742-2094-5-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-5-8</ArticleId><ArticleId IdType="pmc">PMC2292163</ArticleId><ArticleId IdType="pubmed">18304357</ArticleId></ArticleIdList></Reference><Reference><Citation>Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson&#x2019;s disease. Brain. 2008;131:1880&#x2013;1894. doi: 10.1093/brain/awn101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn101</ArticleId><ArticleId IdType="pmc">PMC2442423</ArticleId><ArticleId IdType="pubmed">18504291</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. Caspase-1 causes truncation and aggregation of the Parkinson&#x2019;s disease-associated protein alpha-synuclein. Proc. Natl Acad. Sci. USA. 2016;113:9587&#x2013;9592. doi: 10.1073/pnas.1610099113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1610099113</ArticleId><ArticleId IdType="pmc">PMC5003239</ArticleId><ArticleId IdType="pubmed">27482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P, et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J. Neuroinflamm. 2014;11:94. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadhim H, Deltenre P, Martin JJ, Sebire G. In-situ expression of Interleukin-18 and associated mediators in the human brain of sALS patients: hypothesis for a role for immune-inflammatory mechanisms. Med. Hypotheses. 2016;86:14&#x2013;17. doi: 10.1016/j.mehy.2015.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2015.11.022</ArticleId><ArticleId IdType="pubmed">26804591</ArticleId></ArticleIdList></Reference><Reference><Citation>Debye B, et al. Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice. Brain Pathol. 2018;28:14&#x2013;27. doi: 10.1111/bpa.12467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12467</ArticleId><ArticleId IdType="pmc">PMC8028558</ArticleId><ArticleId IdType="pubmed">27880990</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitzer M, et al. Administration of 17beta-Estradiol improves motoneuron survival and down-regulates inflammasome activation in male SOD1(G93A) ALS mice. Mol. Neurobiol. 2017;54:8429&#x2013;8443. doi: 10.1007/s12035-016-0322-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0322-4</ArticleId><ArticleId IdType="pubmed">27957680</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. Purinergic nerves. Pharmacol. Rev. 1972;24:509&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">4404211</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrowski MJ, et al. Glial purinergic signaling in neurodegeneration. Front. Neurol. 2021;12:654850. doi: 10.3389/fneur.2021.654850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.654850</ArticleId><ArticleId IdType="pmc">PMC8160300</ArticleId><ArticleId IdType="pubmed">34054698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonora M, et al. ATP synthesis and storage. Purinergic Signal. 2012;8:343&#x2013;357. doi: 10.1007/s11302-012-9305-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-012-9305-8</ArticleId><ArticleId IdType="pmc">PMC3360099</ArticleId><ArticleId IdType="pubmed">22528680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall MJ, Dale N. Auto-inhibition of rat parallel fibre-Purkinje cell synapses by activity-dependent adenosine release. J. Physiol. 2007;581:553&#x2013;565. doi: 10.1113/jphysiol.2006.126417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2006.126417</ArticleId><ArticleId IdType="pmc">PMC2075183</ArticleId><ArticleId IdType="pubmed">17347275</ArticleId></ArticleIdList></Reference><Reference><Citation>Badimon A, et al. Negative feedback control of neuronal activity by microglia. Nature. 2020;586:417&#x2013;423. doi: 10.1038/s41586-020-2777-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2777-8</ArticleId><ArticleId IdType="pmc">PMC7577179</ArticleId><ArticleId IdType="pubmed">32999463</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47:15&#x2013;31. doi: 10.1016/j.immuni.2017.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.06.020</ArticleId><ArticleId IdType="pubmed">28723547</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluyter R. The P2X7 receptor. Adv. Exp. Med. Biol. 2017;1051:17&#x2013;53. doi: 10.1007/5584_2017_59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/5584_2017_59</ArticleId><ArticleId IdType="pubmed">28676924</ArticleId></ArticleIdList></Reference><Reference><Citation>Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7) Science. 1996;272:735&#x2013;738. doi: 10.1126/science.272.5262.735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.272.5262.735</ArticleId><ArticleId IdType="pubmed">8614837</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira-Giacomelli A, et al. Role of P2X7 receptors in immune responses during neurodegeneration. Front. Cell. Neurosci. 2021;15:662935. doi: 10.3389/fncel.2021.662935.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.662935</ArticleId><ArticleId IdType="pmc">PMC8187565</ArticleId><ArticleId IdType="pubmed">34122013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz JM, et al. Activation of microglia by amyloid {beta} requires P2X7 receptor expression. J. Immunol. 2009;182:4378&#x2013;4385. doi: 10.4049/jimmunol.0803612.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0803612</ArticleId><ArticleId IdType="pubmed">19299738</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathenani LK, et al. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer&#x2019;s disease. J. Biol. Chem. 2003;278:13309&#x2013;13317. doi: 10.1074/jbc.M209478200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M209478200</ArticleId><ArticleId IdType="pubmed">12551918</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Frailes C, et al. Amyloid peptide induced neuroinflammation increases the P2X7 receptor expression in microglial cells, impacting on its functionality. Front. Cell. Neurosci. 2019;13:143. doi: 10.3389/fncel.2019.00143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00143</ArticleId><ArticleId IdType="pmc">PMC6474397</ArticleId><ArticleId IdType="pubmed">31031598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK, McLarnon JG. Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer&#x2019;s disease. Neuroreport. 2008;19:1715&#x2013;1719. doi: 10.1097/WNR.0b013e3283179333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0b013e3283179333</ArticleId><ArticleId IdType="pubmed">18852683</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin E, et al. New role of P2X7 receptor in an Alzheimer&#x2019;s disease mouse model. Mol. Psychiatry. 2019;24:108&#x2013;125. doi: 10.1038/s41380-018-0108-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0108-3</ArticleId><ArticleId IdType="pmc">PMC6756107</ArticleId><ArticleId IdType="pubmed">29934546</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrenberger PF, et al. Inflammatory pathways in Parkinson&#x2019;s disease; a BNE microarray study. Parkinsons Dis. 2012;2012:214714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3324922</ArticleId><ArticleId IdType="pubmed">22548201</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcellino D, et al. On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson&#x2019;s disease: studies with the P2X(7) receptor antagonist A-438079. J. Neural Transm. 2010;117:681&#x2013;687. doi: 10.1007/s00702-010-0400-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-010-0400-0</ArticleId><ArticleId IdType="pubmed">20387084</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12. doi: 10.1186/1471-2377-6-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-6-12</ArticleId><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ambrosi N, et al. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J. Immunol. 2009;183:4648&#x2013;4656. doi: 10.4049/jimmunol.0901212.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901212</ArticleId><ArticleId IdType="pubmed">19734218</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Amadio S, Montilli C, Volonte C, D&#x2019;Ambrosi N. Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:4102&#x2013;4116. doi: 10.1093/hmg/ddt259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt259</ArticleId><ArticleId IdType="pubmed">23736299</ArticleId></ArticleIdList></Reference><Reference><Citation>Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 2021;21:548&#x2013;569. doi: 10.1038/s41577-021-00524-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00524-z</ArticleId><ArticleId IdType="pmc">PMC8029610</ArticleId><ArticleId IdType="pubmed">33833439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan D, Jiang W, Hao J. Research advances in how the cGAS-STING pathway controls the cellular inflammatory response. Front. Immunol. 2020;11:615. doi: 10.3389/fimmu.2020.00615.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00615</ArticleId><ArticleId IdType="pmc">PMC7198750</ArticleId><ArticleId IdType="pubmed">32411126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786&#x2013;791. doi: 10.1126/science.1232458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232458</ArticleId><ArticleId IdType="pmc">PMC3863629</ArticleId><ArticleId IdType="pubmed">23258413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455:674&#x2013;678. doi: 10.1038/nature07317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07317</ArticleId><ArticleId IdType="pmc">PMC2804933</ArticleId><ArticleId IdType="pubmed">18724357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai K, et al. Activation of STING requires palmitoylation at the Golgi. Nat. Commun. 2016;7:11932. doi: 10.1038/ncomms11932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11932</ArticleId><ArticleId IdType="pmc">PMC4919521</ArticleId><ArticleId IdType="pubmed">27324217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, et al. Structural basis of STING binding with and phosphorylation by TBK1. Nature. 2019;567:394&#x2013;398. doi: 10.1038/s41586-019-1000-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1000-2</ArticleId><ArticleId IdType="pmc">PMC6862768</ArticleId><ArticleId IdType="pubmed">30842653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, et al. A conserved PLPLRT/SD motif of STING mediates the recruitment and activation of TBK1. Nature. 2019;569:718&#x2013;722. doi: 10.1038/s41586-019-1228-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1228-x</ArticleId><ArticleId IdType="pmc">PMC6596994</ArticleId><ArticleId IdType="pubmed">31118511</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 2015;347:aaa2630. doi: 10.1126/science.aaa2630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa2630</ArticleId><ArticleId IdType="pubmed">25636800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Dobbs N, Yang K, Yan N. Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion. Immunity. 2020;53:115&#x2013;126.e115. doi: 10.1016/j.immuni.2020.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.06.009</ArticleId><ArticleId IdType="pmc">PMC7365768</ArticleId><ArticleId IdType="pubmed">32640258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaidt MM, et al. The DNA inflammasome in human myeloid cells is initiated by a STING-cell death program upstream of NLRP3. Cell. 2017;171:1110&#x2013;1124.e1118. doi: 10.1016/j.cell.2017.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.09.039</ArticleId><ArticleId IdType="pmc">PMC5901709</ArticleId><ArticleId IdType="pubmed">29033128</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui X, et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature. 2019;567:262&#x2013;266. doi: 10.1038/s41586-019-1006-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1006-9</ArticleId><ArticleId IdType="pmc">PMC9417302</ArticleId><ArticleId IdType="pubmed">30842662</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Kang JH, Lee S. Autophagy in neurodegenerative diseases: a hunter for aggregates. Int. J. Mol. Sci. 2020;21:3369 . doi: 10.3390/ijms21093369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093369</ArticleId><ArticleId IdType="pmc">PMC7247013</ArticleId><ArticleId IdType="pubmed">32397599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie KJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461&#x2013;465. doi: 10.1038/nature23449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23449</ArticleId><ArticleId IdType="pmc">PMC5870830</ArticleId><ArticleId IdType="pubmed">28738408</ArticleId></ArticleIdList></Reference><Reference><Citation>West AP, et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553&#x2013;557. doi: 10.1038/nature14156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14156</ArticleId><ArticleId IdType="pmc">PMC4409480</ArticleId><ArticleId IdType="pubmed">25642965</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreeva L, et al. cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein-DNA ladders. Nature. 2017;549:394&#x2013;398. doi: 10.1038/nature23890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23890</ArticleId><ArticleId IdType="pubmed">28902841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, et al. NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer&#x2019;s disease via cGAS-STING. Proc. Natl Acad. Sci. USA. 2021;118:e2011226118. doi: 10.1073/pnas.2011226118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2011226118</ArticleId><ArticleId IdType="pmc">PMC8449423</ArticleId><ArticleId IdType="pubmed">34497121</ArticleId></ArticleIdList></Reference><Reference><Citation>Larrick JW, Mendelsohn AR. Modulation of cGAS-STING Pathway by Nicotinamide Riboside in Alzheimer&#x2019;s Disease. Rejuvenation Res. 2021;24:397&#x2013;402. doi: 10.1089/rej.2021.0062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2021.0062</ArticleId><ArticleId IdType="pubmed">34694148</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, et al. Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation. Nat. Commun. 2021;12:6565. doi: 10.1038/s41467-021-26851-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26851-2</ArticleId><ArticleId IdType="pmc">PMC8592984</ArticleId><ArticleId IdType="pubmed">34782623</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, et al. Activation of innate immune cGAS-STING pathway contributes to Alzheimer&#x2019;s pathogenesis in 5&#xd7;FAD mice. Nat. Aging. 2023;3:202&#x2013;212. doi: 10.1038/s43587-022-00337-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-022-00337-2</ArticleId><ArticleId IdType="pubmed">37118112</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Xu W, Cheng H, Yuan H, Tan X. Efficacy and mechanism of cGAMP to suppress Alzheimer&#x2019;s disease by elevating TREM2. Brain. Behav. Immun. 2019;81:495&#x2013;508. doi: 10.1016/j.bbi.2019.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2019.07.004</ArticleId><ArticleId IdType="pubmed">31283973</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinkle JT, et al. STING mediates neurodegeneration and neuroinflammation in nigrostriatal alpha-synucleinopathy. Proc. Natl Acad. Sci. USA. 2022;119:e2118819119. doi: 10.1073/pnas.2118819119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2118819119</ArticleId><ArticleId IdType="pmc">PMC9169780</ArticleId><ArticleId IdType="pubmed">35394877</ArticleId></ArticleIdList></Reference><Reference><Citation>Standaert DG, Childers GM. Alpha-synuclein-mediated DNA damage, STING activation, and neuroinflammation in Parkinson&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2022;119:e2204058119. doi: 10.1073/pnas.2204058119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2204058119</ArticleId><ArticleId IdType="pmc">PMC9170025</ArticleId><ArticleId IdType="pubmed">35446614</ArticleId></ArticleIdList></Reference><Reference><Citation>Szego EM, et al. Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice. Elife. 2022;11:e81943. doi: 10.7554/eLife.81943.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.81943</ArticleId><ArticleId IdType="pmc">PMC9767458</ArticleId><ArticleId IdType="pubmed">36314770</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585:96&#x2013;101. doi: 10.1038/s41586-020-2625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunmokun, G. et al. The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer&#x2019;s Disease. Cells10 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8534363</ArticleId><ArticleId IdType="pubmed">34685770</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiurchiu V, Maccarrone M. Bioactive lipids as modulators of immunity, inflammation and emotions. Curr. Opin. Pharmacol. 2016;29:54&#x2013;62. doi: 10.1016/j.coph.2016.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2016.06.005</ArticleId><ArticleId IdType="pubmed">27372887</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiurchiu V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front. Immunol. 2018;9:38. doi: 10.3389/fimmu.2018.00038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00038</ArticleId><ArticleId IdType="pmc">PMC5797284</ArticleId><ArticleId IdType="pubmed">29434586</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore AH, et al. Non-steroidal anti-inflammatory drugs in Alzheimer&#x2019;s disease and parkinson&#x2019;s disease: reconsidering the role of neuroinflammation. Pharm. (Basel) 2010;3:1812&#x2013;1841. doi: 10.3390/ph3061812.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph3061812</ArticleId><ArticleId IdType="pmc">PMC4033954</ArticleId><ArticleId IdType="pubmed">27713331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira I, Falcato F, Bandarra N, Rauter AP. Resolvins, protectins, and maresins: DHA-derived specialized pro-resolving mediators, biosynthetic pathways, synthetic approaches, and their role in inflammation. Molecules. 2022;27:1677. doi: 10.3390/molecules27051677.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27051677</ArticleId><ArticleId IdType="pmc">PMC8912121</ArticleId><ArticleId IdType="pubmed">35268778</ArticleId></ArticleIdList></Reference><Reference><Citation>Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92&#x2013;101. doi: 10.1038/nature13479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13479</ArticleId><ArticleId IdType="pmc">PMC4263681</ArticleId><ArticleId IdType="pubmed">24899309</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat. Rev. Immunol. 2015;15:511&#x2013;523. doi: 10.1038/nri3859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3859</ArticleId><ArticleId IdType="pmc">PMC4606863</ArticleId><ArticleId IdType="pubmed">26139350</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2001;2:612&#x2013;619. doi: 10.1038/89759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/89759</ArticleId><ArticleId IdType="pubmed">11429545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, et al. N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer&#x2019;s disease. Nat. Commun. 2020;11:2358. doi: 10.1038/s41467-020-16080-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16080-4</ArticleId><ArticleId IdType="pmc">PMC7217877</ArticleId><ArticleId IdType="pubmed">32398649</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattahi MJ, Mirshafiey A. Positive and negative effects of prostaglandins in Alzheimer&#x2019;s disease. Psychiatry Clin. Neurosci. 2014;68:50&#x2013;60. doi: 10.1111/pcn.12092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pcn.12092</ArticleId><ArticleId IdType="pubmed">23992456</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, et al. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J. Immunol. 2010;184:7207&#x2013;7218. doi: 10.4049/jimmunol.0903487.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903487</ArticleId><ArticleId IdType="pmc">PMC3103215</ArticleId><ArticleId IdType="pubmed">20483760</ArticleId></ArticleIdList></Reference><Reference><Citation>Biringer RG. The role of eicosanoids in Alzheimer&#x2019;s disease. Int. J. Environ. Res. Public Health. 2019;16:2560. doi: 10.3390/ijerph16142560.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph16142560</ArticleId><ArticleId IdType="pmc">PMC6678666</ArticleId><ArticleId IdType="pubmed">31323750</ArticleId></ArticleIdList></Reference><Reference><Citation>Famitafreshi H, Karimian M. Prostaglandins as the agents that modulate the course of brain disorders. Degener. Neurol. Neuromuscul. Dis. 2020;10:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6970614</ArticleId><ArticleId IdType="pubmed">32021549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Resolution of inflammation is altered in Alzheimer&#x2019;s disease. Alzheimers Dement. 2015;11:40&#x2013;50. doi: 10.1016/j.jalz.2013.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.12.024</ArticleId><ArticleId IdType="pmc">PMC4275415</ArticleId><ArticleId IdType="pubmed">24530025</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre C, et al. Receptors for pro-resolving mediators are increased in Alzheimer&#x2019;s disease brain. Brain Pathol. 2020;30:614&#x2013;640. doi: 10.1111/bpa.12812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12812</ArticleId><ArticleId IdType="pmc">PMC8018009</ArticleId><ArticleId IdType="pubmed">31912564</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazawa K, et al. Alzheimer&#x2019;s disease and specialized pro-resolving lipid mediators: Do MaR1, RvD1, and NPD1 show promise for prevention and treatment? Int. J. Mol. Sci. 2020;21:5783. doi: 10.3390/ijms21165783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21165783</ArticleId><ArticleId IdType="pmc">PMC7460933</ArticleId><ArticleId IdType="pubmed">32806612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M, et al. Pro-resolving lipid mediators improve neuronal survival and increase Abeta42 phagocytosis. Mol. Neurobiol. 2016;53:2733&#x2013;2749. doi: 10.1007/s12035-015-9544-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9544-0</ArticleId><ArticleId IdType="pmc">PMC4824659</ArticleId><ArticleId IdType="pubmed">26650044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci A, et al. Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer&#x2019;s disease. Exp. Neurol. 2018;300:111&#x2013;120. doi: 10.1016/j.expneurol.2017.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.11.005</ArticleId><ArticleId IdType="pubmed">29126887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Maresin 1 attenuates pro-inflammatory activation induced by beta-amyloid and stimulates its uptake. J. Cell. Mol. Med. 2021;25:434&#x2013;447. doi: 10.1111/jcmm.16098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.16098</ArticleId><ArticleId IdType="pmc">PMC7810927</ArticleId><ArticleId IdType="pubmed">33225628</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, et al. Maresin1 decreased microglial chemotaxis and ameliorated inflammation induced by Amyloid-beta42 in neuron-microglia co-culture models. J. Alzheimer&#x2019;s Dis. 2020;73:503&#x2013;515. doi: 10.3233/JAD-190682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190682</ArticleId><ArticleId IdType="pubmed">31796671</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, et al. Maresin 1 improves cognitive decline and ameliorates inflammation in a mouse model of Alzheimer&#x2019;s disease. Front. Cell. Neurosci. 2019;13:466. doi: 10.3389/fncel.2019.00466.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00466</ArticleId><ArticleId IdType="pmc">PMC6803487</ArticleId><ArticleId IdType="pubmed">31680874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma-mediated mechanisms in Alzheimer&#x2019;s disease models. PLoS One. 2011;6:e15816. doi: 10.1371/journal.pone.0015816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015816</ArticleId><ArticleId IdType="pmc">PMC3016440</ArticleId><ArticleId IdType="pubmed">21246057</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark DT, Bazan NG. Neuroprotectin D1 induces neuronal survival and downregulation of amyloidogenic processing in Alzheimer&#x2019;s disease cellular models. Mol. Neurobiol. 2011;43:131&#x2013;138. doi: 10.1007/s12035-011-8174-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-011-8174-4</ArticleId><ArticleId IdType="pubmed">21431475</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre C, et al. Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in App(NL-G-F/NL-G-F) mice. Commun. Biol. 2022;5:245. doi: 10.1038/s42003-022-03169-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03169-3</ArticleId><ArticleId IdType="pmc">PMC8938447</ArticleId><ArticleId IdType="pubmed">35314851</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Zhang Y, Zhang R, Qiao S, Fan J. Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson&#x2019;s disease rat model. Biochem. Biophys. Res. Commun. 2015;460:799&#x2013;805. doi: 10.1016/j.bbrc.2015.03.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2015.03.109</ArticleId><ArticleId IdType="pubmed">25824039</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, et al. ANXA1 and the risk for early-onset Parkinson&#x2019;s disease. Neurobiol. Aging. 2022;112:212&#x2013;214. doi: 10.1016/j.neurobiolaging.2022.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2022.01.009</ArticleId><ArticleId IdType="pubmed">35240489</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am. J. Neurodegener. Dis. 2012;1:60&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560453</ArticleId><ArticleId IdType="pubmed">22787561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohuchi K, et al. A docosahexaenoic acid-derived pro-resolving agent, maresin 1, protects motor neuron cells death. Neurochem. Res. 2018;43:1413&#x2013;1423. doi: 10.1007/s11064-018-2556-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-018-2556-1</ArticleId><ArticleId IdType="pubmed">29797139</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat. Rev. Drug Discov. 2016;15:551&#x2013;567. doi: 10.1038/nrd.2016.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.39</ArticleId><ArticleId IdType="pubmed">27020098</ArticleId></ArticleIdList></Reference><Reference><Citation>Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005;6:1191&#x2013;1197. doi: 10.1038/ni1276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1276</ArticleId><ArticleId IdType="pubmed">16369558</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner M, et al. Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome. FASEB J. 2019;33:6140&#x2013;6153. doi: 10.1096/fj.201802509R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201802509R</ArticleId><ArticleId IdType="pmc">PMC6988863</ArticleId><ArticleId IdType="pubmed">30735438</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiberi M, Chiurchiu V. Specialized pro-resolving lipid mediators and glial cells: emerging candidates for brain homeostasis and repair. Front. Cell. Neurosci. 2021;15:673549. doi: 10.3389/fncel.2021.673549.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.673549</ArticleId><ArticleId IdType="pmc">PMC8107215</ArticleId><ArticleId IdType="pubmed">33981203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiurchiu V, et al. Lipidomics of bioactive lipids in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: where are we? Int. J. Mol. Sci. 2022;23:6235. doi: 10.3390/ijms23116235.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23116235</ArticleId><ArticleId IdType="pmc">PMC9181703</ArticleId><ArticleId IdType="pubmed">35682914</ArticleId></ArticleIdList></Reference><Reference><Citation>Liy PM, Puzi NNA, Jose S, Vidyadaran S. Nitric oxide modulation in neuroinflammation and the role of mesenchymal stem cells. Exp. Biol. Med. (Maywood) 2021;246:2399&#x2013;2406. doi: 10.1177/1535370221997052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370221997052</ArticleId><ArticleId IdType="pmc">PMC8606960</ArticleId><ArticleId IdType="pubmed">33715528</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman JW. Nitric oxide in immunity and inflammation. Int. Immunopharmacol. 2001;1:1397&#x2013;1406. doi: 10.1016/S1567-5769(01)00086-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1567-5769(01)00086-8</ArticleId><ArticleId IdType="pubmed">11515807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wink DA, et al. Nitric oxide and redox mechanisms in the immune response. J. Leukoc. Biol. 2011;89:873&#x2013;891. doi: 10.1189/jlb.1010550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1010550</ArticleId><ArticleId IdType="pmc">PMC3100761</ArticleId><ArticleId IdType="pubmed">21233414</ArticleId></ArticleIdList></Reference><Reference><Citation>Justo AFO, Suemoto CK. The modulation of neuroinflammation by inducible nitric oxide synthase. J. Cell Commun. Signal. 2022;16:155&#x2013;158. doi: 10.1007/s12079-021-00663-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12079-021-00663-x</ArticleId><ArticleId IdType="pmc">PMC8891402</ArticleId><ArticleId IdType="pubmed">35031946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace JL, Ianaro A, Flannigan KL, Cirino G. Gaseous mediators in resolution of inflammation. Semin. Immunol. 2015;27:227&#x2013;233. doi: 10.1016/j.smim.2015.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2015.05.004</ArticleId><ArticleId IdType="pubmed">26095908</ArticleId></ArticleIdList></Reference><Reference><Citation>Saio M, Radoja S, Marino M, Frey AB. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol. 2001;167:5583&#x2013;5593. doi: 10.4049/jimmunol.167.10.5583.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.10.5583</ArticleId><ArticleId IdType="pubmed">11698429</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaeli J, et al. Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFalpha and NO-dependent mechanism, promoting a tumor-supportive environment. Oncoimmunology. 2017;6:e1356965. doi: 10.1080/2162402X.2017.1356965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1356965</ArticleId><ArticleId IdType="pmc">PMC5674962</ArticleId><ArticleId IdType="pubmed">29147615</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul-Clark MJ, Gilroy DW, Willis D, Willoughby DA, Tomlinson A. Nitric oxide synthase inhibitors have opposite effects on acute inflammation depending on their route of administration. J. Immunol. 2001;166:1169&#x2013;1177. doi: 10.4049/jimmunol.166.2.1169.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.2.1169</ArticleId><ArticleId IdType="pubmed">11145698</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuste JE, Tarragon E, Campuzano CM, Ros-Bernal F. Implications of glial nitric oxide in neurodegenerative diseases. Front. Cell. Neurosci. 2015;9:322. doi: 10.3389/fncel.2015.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00322</ArticleId><ArticleId IdType="pmc">PMC4538301</ArticleId><ArticleId IdType="pubmed">26347610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer MP, et al. Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. Neuron. 2011;71:833&#x2013;844. doi: 10.1016/j.neuron.2011.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.07.001</ArticleId><ArticleId IdType="pubmed">21903077</ArticleId></ArticleIdList></Reference><Reference><Citation>Guivernau B, et al. Amyloid-beta peptide nitrotyrosination stabilizes oligomers and enhances NMDAR-mediated toxicity. J. Neurosci. 2016;36:11693&#x2013;11703. doi: 10.1523/JNEUROSCI.1081-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1081-16.2016</ArticleId><ArticleId IdType="pmc">PMC6705640</ArticleId><ArticleId IdType="pubmed">27852777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu HY, Hong FF, Yang SL. The roles of nitric oxide synthase/nitric oxide pathway in the pathology of vascular dementia and related therapeutic approaches. Int. J. Mol. Sci. 2021;22:4540. doi: 10.3390/ijms22094540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094540</ArticleId><ArticleId IdType="pmc">PMC8123648</ArticleId><ArticleId IdType="pubmed">33926146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind M, et al. Inducible nitric oxide synthase: Good or bad? Biomed. Pharmacother. 2017;93:370&#x2013;375. doi: 10.1016/j.biopha.2017.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.06.036</ArticleId><ArticleId IdType="pubmed">28651238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan C, et al. Protection from Alzheimer&#x2019;s-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J. Exp. Med. 2005;202:1163&#x2013;1169. doi: 10.1084/jem.20051529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20051529</ArticleId><ArticleId IdType="pmc">PMC2213235</ArticleId><ArticleId IdType="pubmed">16260491</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, et al. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2006;103:12867&#x2013;12872. doi: 10.1073/pnas.0601075103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0601075103</ArticleId><ArticleId IdType="pmc">PMC1550768</ArticleId><ArticleId IdType="pubmed">16908860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunot S, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson&#x2019;s disease. Neuroscience. 1996;72:355&#x2013;363. doi: 10.1016/0306-4522(95)00578-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(95)00578-1</ArticleId><ArticleId IdType="pubmed">8737406</ArticleId></ArticleIdList></Reference><Reference><Citation>Broom L, et al. Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic. Biol. Med. 2011;50:633&#x2013;640. doi: 10.1016/j.freeradbiomed.2010.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2010.12.026</ArticleId><ArticleId IdType="pubmed">21185368</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, et al. Apelin-36 mediates neuroprotective effects by regulating oxidative stress, autophagy and apoptosis in MPTP-induced Parkinson&#x2019;s disease model mice. Brain Res. 2020;1726:146493. doi: 10.1016/j.brainres.2019.146493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146493</ArticleId><ArticleId IdType="pubmed">31586624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapias V, et al. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell. Mol. Life Sci. 2017;74:2851&#x2013;2874. doi: 10.1007/s00018-017-2541-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2541-x</ArticleId><ArticleId IdType="pmc">PMC5524146</ArticleId><ArticleId IdType="pubmed">28534083</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthwal MK, Srivastava N, Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson&#x2019;s disease in the rat. Redox Rep. 2001;6:297&#x2013;302. doi: 10.1179/135100001101536436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/135100001101536436</ArticleId><ArticleId IdType="pubmed">11778847</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 1995;64:936&#x2013;939. doi: 10.1046/j.1471-4159.1995.64020936.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1995.64020936.x</ArticleId><ArticleId IdType="pubmed">7530297</ArticleId></ArticleIdList></Reference><Reference><Citation>Aras S, Tanriover G, Aslan M, Yargicoglu P, Agar A. The role of nitric oxide on visual-evoked potentials in MPTP-induced Parkinsonism in mice. Neurochem. Int. 2014;72:48&#x2013;57. doi: 10.1016/j.neuint.2014.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2014.04.014</ArticleId><ArticleId IdType="pubmed">24795109</ArticleId></ArticleIdList></Reference><Reference><Citation>Titze-de-Almeida R, et al. Suppressing nNOS enzyme by small-interfering RNAs protects SH-SY5Y cells and nigral dopaminergic neurons from 6-OHDA injury. Neurotox. Res. 2019;36:117&#x2013;131. doi: 10.1007/s12640-019-00043-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-019-00043-9</ArticleId><ArticleId IdType="pubmed">31041676</ArticleId></ArticleIdList></Reference><Reference><Citation>Monterey MD, Wei H, Wu X, Wu JQ. The many faces of astrocytes in Alzheimer&#x2019;s disease. Front. Neurol. 2021;12:619626. doi: 10.3389/fneur.2021.619626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.619626</ArticleId><ArticleId IdType="pmc">PMC8438135</ArticleId><ArticleId IdType="pubmed">34531807</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer&#x2019;s disease. J. Neuroinflamm. 2022;19:206. doi: 10.1186/s12974-022-02565-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02565-0</ArticleId><ArticleId IdType="pmc">PMC9382837</ArticleId><ArticleId IdType="pubmed">35978311</ArticleId></ArticleIdList></Reference><Reference><Citation>Suo Z, et al. Alzheimer&#x2019;s beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res. 1998;807:110&#x2013;117. doi: 10.1016/S0006-8993(98)00780-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(98)00780-X</ArticleId><ArticleId IdType="pubmed">9757011</ArticleId></ArticleIdList></Reference><Reference><Citation>Vukic V, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer&#x2019;s brain is mediated by the JNK-AP1 signaling pathway. Neurobiol. Dis. 2009;34:95&#x2013;106. doi: 10.1016/j.nbd.2008.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.12.007</ArticleId><ArticleId IdType="pmc">PMC2720310</ArticleId><ArticleId IdType="pubmed">19162185</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira HA, Kumar P, Grammas P. Expression of CAP37, a novel inflammatory mediator, in Alzheimer&#x2019;s disease. Neurobiol. Aging. 1996;17:753&#x2013;759. doi: 10.1016/S0197-4580(96)00118-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(96)00118-2</ArticleId><ArticleId IdType="pubmed">8892348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau SF, Cao H, Fu AKY, Ip NY. Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2020;117:25800&#x2013;25809. doi: 10.1073/pnas.2008762117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2008762117</ArticleId><ArticleId IdType="pmc">PMC7568283</ArticleId><ArticleId IdType="pubmed">32989152</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter KN, et al. Medroxyprogesterone acetate impairs amyloid beta degradation in a matrix metalloproteinase-9 dependent manner. Front. Aging Neurosci. 2020;12:92. doi: 10.3389/fnagi.2020.00092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00092</ArticleId><ArticleId IdType="pmc">PMC7155169</ArticleId><ArticleId IdType="pubmed">32317959</ArticleId></ArticleIdList></Reference><Reference><Citation>Voirin AC, Perek N, Roche F. Inflammatory stress induced by a combination of cytokines (IL-6, IL-17, TNF-alpha) leads to a loss of integrity on bEnd.3 endothelial cells in vitro BBB model. Brain Res. 2020;1730:146647. doi: 10.1016/j.brainres.2020.146647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2020.146647</ArticleId><ArticleId IdType="pubmed">31911168</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana A, et al. Increased Type I interferon signaling and brain endothelial barrier dysfunction in an experimental model of Alzheimer&#x2019;s disease. Sci. Rep. 2022;12:16488. doi: 10.1038/s41598-022-20889-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-20889-y</ArticleId><ArticleId IdType="pmc">PMC9526723</ArticleId><ArticleId IdType="pubmed">36182964</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalvi S, et al. Exogenous arachidonic acid mediates permeability of human brain microvessel endothelial cells through prostaglandin E2 activation of EP3 and EP4 receptors. J. Neurochem. 2015;135:867&#x2013;879. doi: 10.1111/jnc.13117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13117</ArticleId><ArticleId IdType="pubmed">25865705</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata F, et al. Oncostatin M-induced blood-brain barrier impairment is due to prolonged activation of STAT3 signaling in vitro. J. Cell. Biochem. 2018;119:9055&#x2013;9063. doi: 10.1002/jcb.27162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.27162</ArticleId><ArticleId IdType="pubmed">30076740</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosjean S, et al. Retinoic acid attenuates inducible nitric oxide synthase (NOS2) activation in cultured rat cardiac myocytes and microvascular endothelial cells. J. Mol. Cell. Cardiol. 2001;33:933&#x2013;945. doi: 10.1006/jmcc.2001.1356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmcc.2001.1356</ArticleId><ArticleId IdType="pubmed">11343416</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorheim MA, Tracey WR, Pollock JS, Grammas P. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer&#x2019;s disease. Biochem. Biophys. Res. Commun. 1994;205:659&#x2013;665. doi: 10.1006/bbrc.1994.2716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1994.2716</ArticleId><ArticleId IdType="pubmed">7528015</ArticleId></ArticleIdList></Reference><Reference><Citation>Askarova S, Yang X, Sheng W, Sun GY, Lee JC. Role of Abeta-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A(2) activation in astrocytes and cerebral endothelial cells. Neuroscience. 2011;199:375&#x2013;385. doi: 10.1016/j.neuroscience.2011.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.09.038</ArticleId><ArticleId IdType="pmc">PMC3237818</ArticleId><ArticleId IdType="pubmed">21978883</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreibelt G, et al. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J. 2007;21:3666&#x2013;3676. doi: 10.1096/fj.07-8329com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.07-8329com</ArticleId><ArticleId IdType="pubmed">17586731</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178&#x2013;201. doi: 10.1016/j.neuron.2008.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.01.003</ArticleId><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto J, et al. Serum amyloid A-induced blood-brain barrier dysfunction associated with decreased claudin-5 expression in rat brain endothelial cells and its inhibition by high-density lipoprotein in vitro. Neurosci. Lett. 2020;738:135352. doi: 10.1016/j.neulet.2020.135352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2020.135352</ArticleId><ArticleId IdType="pubmed">32931862</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra R, Singh SK. HIV-1 Tat C modulates expression of miRNA-101 to suppress VE-cadherin in human brain microvascular endothelial cells. J. Neurosci. 2013;33:5992&#x2013;6000. doi: 10.1523/JNEUROSCI.4796-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4796-12.2013</ArticleId><ArticleId IdType="pmc">PMC6618916</ArticleId><ArticleId IdType="pubmed">23554480</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohman EM, Frohman TC, Gupta S, de Fougerolles A, van den Noort S. Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer&#x2019;s disease. J. Neurol. Sci. 1991;106:105&#x2013;111. doi: 10.1016/0022-510X(91)90202-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(91)90202-I</ArticleId><ArticleId IdType="pubmed">1685745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallmann BA, et al. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain. 2000;123:687&#x2013;697. doi: 10.1093/brain/123.4.687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.4.687</ArticleId><ArticleId IdType="pubmed">10734000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbie MS, Hurst RD, Klein NJ, Surtees RA. Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-alpha in an in vitro model of the blood-brain barrier. Brain Res. 1999;830:330&#x2013;336. doi: 10.1016/S0006-8993(99)01436-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(99)01436-5</ArticleId><ArticleId IdType="pubmed">10366690</ArticleId></ArticleIdList></Reference><Reference><Citation>Propson NE, Roy ER, Litvinchuk A, Kohl J, Zheng H. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J. Clin. Invest. 2021;131:e140966. doi: 10.1172/JCI140966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140966</ArticleId><ArticleId IdType="pmc">PMC7773352</ArticleId><ArticleId IdType="pubmed">32990682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia K, Ahmad S, Kindelin A, Ducruet AF. Complement C3a receptor-mediated vascular dysfunction: a complex interplay between aging and neurodegeneration. J. Clin. Invest. 2021;131:e144348. doi: 10.1172/JCI144348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI144348</ArticleId><ArticleId IdType="pmc">PMC7773380</ArticleId><ArticleId IdType="pubmed">33393493</ArticleId></ArticleIdList></Reference><Reference><Citation>Perner C, et al. Plasma VCAM1 levels correlate with disease severity in Parkinson&#x2019;s disease. J. Neuroinflamm. 2019;16:94. doi: 10.1186/s12974-019-1482-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1482-8</ArticleId><ArticleId IdType="pmc">PMC6507178</ArticleId><ArticleId IdType="pubmed">31068198</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, et al. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J. Immunol. 2009;182:5778&#x2013;5788. doi: 10.4049/jimmunol.0803013.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0803013</ArticleId><ArticleId IdType="pubmed">19380826</ArticleId></ArticleIdList></Reference><Reference><Citation>Stock AJ, Kasus-Jacobi A, Pereira HA. The role of neutrophil granule proteins in neuroinflammation and Alzheimer&#x2019;s disease. J. Neuroinflamm. 2018;15:240. doi: 10.1186/s12974-018-1284-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1284-4</ArticleId><ArticleId IdType="pmc">PMC6112130</ArticleId><ArticleId IdType="pubmed">30149799</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasnow SM, Knoll JG, Verghese SC, Levasseur PR, Marks DL. Amplification and propagation of interleukin-1beta signaling by murine brain endothelial and glial cells. J. Neuroinflamm. 2017;14:133. doi: 10.1186/s12974-017-0908-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0908-4</ArticleId><ArticleId IdType="pmc">PMC5494131</ArticleId><ArticleId IdType="pubmed">28668091</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, et al. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:111&#x2013;120. doi: 10.1007/s00401-012-1039-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1039-8</ArticleId><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, et al. Identification of early pericyte loss and vascular amyloidosis in Alzheimer&#x2019;s disease retina. Acta Neuropathol. 2020;139:813&#x2013;836. doi: 10.1007/s00401-020-02134-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02134-w</ArticleId><ArticleId IdType="pmc">PMC7181564</ArticleId><ArticleId IdType="pubmed">32043162</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark K, et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and &#x2019;instruct&#x2019; them with pattern-recognition and motility programs. Nat. Immunol. 2013;14:41&#x2013;51. doi: 10.1038/ni.2477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2477</ArticleId><ArticleId IdType="pubmed">23179077</ArticleId></ArticleIdList></Reference><Reference><Citation>Guijarro-Munoz I, Compte M, Alvarez-Cienfuegos A, Alvarez-Vallina L, Sanz L. Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-kappaB signaling pathway and proinflammatory response in human pericytes. J. Biol. Chem. 2014;289:2457&#x2013;2468. doi: 10.1074/jbc.M113.521161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.521161</ArticleId><ArticleId IdType="pmc">PMC3900988</ArticleId><ArticleId IdType="pubmed">24307174</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, et al. Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer&#x2019;s disease. Mol. Ther. 2022;30:1451&#x2013;1464. doi: 10.1016/j.ymthe.2022.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.01.023</ArticleId><ArticleId IdType="pmc">PMC9077320</ArticleId><ArticleId IdType="pubmed">35038582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Townsend KP, Obregon DF, Humphrey J, Mullan M. Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat. 2002;70:1&#x2013;12. doi: 10.1016/S0090-6980(02)00111-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-6980(02)00111-9</ArticleId><ArticleId IdType="pubmed">12428674</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, et al. APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer&#x2019;s mice via cyclophilin A independently of amyloid-beta. Nat. Aging. 2021;1:506&#x2013;520. doi: 10.1038/s43587-021-00073-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-021-00073-z</ArticleId><ArticleId IdType="pmc">PMC8920485</ArticleId><ArticleId IdType="pubmed">35291561</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeek MM, et al. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer&#x2019;s disease. Am. J. Pathol. 1994;144:104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887111</ArticleId><ArticleId IdType="pubmed">7904796</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday MR, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer&#x2019;s disease. J. Cereb. Blood Flow. Metab. 2016;36:216&#x2013;227. doi: 10.1038/jcbfm.2015.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2015.44</ArticleId><ArticleId IdType="pmc">PMC4758554</ArticleId><ArticleId IdType="pubmed">25757756</ArticleId></ArticleIdList></Reference><Reference><Citation>Persidsky Y, et al. Dysfunction of brain pericytes in chronic neuroinflammation. J. Cereb. Blood Flow. Metab. 2016;36:794&#x2013;807. doi: 10.1177/0271678X15606149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X15606149</ArticleId><ArticleId IdType="pmc">PMC4821019</ArticleId><ArticleId IdType="pubmed">26661157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409&#x2013;427. doi: 10.1016/j.neuron.2010.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.09.043</ArticleId><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat. Commun. 2013;4:2932. doi: 10.1038/ncomms3932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3932</ArticleId><ArticleId IdType="pmc">PMC3945879</ArticleId><ArticleId IdType="pubmed">24336108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricard N, et al. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. Circulation. 2014;129:1586&#x2013;1597. doi: 10.1161/CIRCULATIONAHA.113.007469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.007469</ArticleId><ArticleId IdType="pubmed">24481949</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopinathan G, et al. Interleukin-6 stimulates defective angiogenesis. Cancer Res. 2015;75:3098&#x2013;3107. doi: 10.1158/0008-5472.CAN-15-1227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-15-1227</ArticleId><ArticleId IdType="pmc">PMC4527186</ArticleId><ArticleId IdType="pubmed">26081809</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, et al. The amyotrophic lateral sclerosis-linked protein TDP-43 regulates interleukin-6 cytokine production by human brain pericytes. Mol. Cell Neurosci. 2022;123:103768. doi: 10.1016/j.mcn.2022.103768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2022.103768</ArticleId><ArticleId IdType="pubmed">36038081</ArticleId></ArticleIdList></Reference><Reference><Citation>Torok O, et al. Pericytes regulate vascular immune homeostasis in the CNS. Proc. Natl. Acad. Sci. USA. 2021;118:e2016587118. doi: 10.1073/pnas.2016587118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2016587118</ArticleId><ArticleId IdType="pmc">PMC7958247</ArticleId><ArticleId IdType="pubmed">33653955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozma M, et al. Cerebral pericytes and endothelial cells communicate through inflammasome-dependent signals. Int. J. Mol. Sci. 2021;22:6122. doi: 10.3390/ijms22116122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116122</ArticleId><ArticleId IdType="pmc">PMC8201302</ArticleId><ArticleId IdType="pubmed">34204159</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J, Jansson D, Smyth LC, Dragunow M. Brain pericytes as mediators of neuroinflammation. Trends Pharmacol. Sci. 2017;38:291&#x2013;304. doi: 10.1016/j.tips.2016.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2016.12.001</ArticleId><ArticleId IdType="pubmed">28017362</ArticleId></ArticleIdList></Reference><Reference><Citation>Laredo F, Plebanski J, Tedeschi A. Pericytes: problems and promises for CNS repair. Front. Cell. Neurosci. 2019;13:546. doi: 10.3389/fncel.2019.00546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00546</ArticleId><ArticleId IdType="pmc">PMC6908836</ArticleId><ArticleId IdType="pubmed">31866833</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerganova G, Riddell A, Miller AA. CNS border-associated macrophages in the homeostatic and ischaemic brain. Pharmacol. Ther. 2022;240:108220. doi: 10.1016/j.pharmthera.2022.108220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2022.108220</ArticleId><ArticleId IdType="pubmed">35667516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity. 2018;48:380&#x2013;395.e386. doi: 10.1016/j.immuni.2018.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.01.011</ArticleId><ArticleId IdType="pubmed">29426702</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordao MJC, et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science. 2019;363:eaat7554. doi: 10.1126/science.aat7554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat7554</ArticleId><ArticleId IdType="pubmed">30679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mato M, et al. Involvement of specific macrophage-lineage cells surrounding arterioles in barrier and scavenger function in brain cortex. Proc. Natl Acad. Sci. USA. 1996;93:3269&#x2013;3274. doi: 10.1073/pnas.93.8.3269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.8.3269</ArticleId><ArticleId IdType="pmc">PMC39595</ArticleId><ArticleId IdType="pubmed">8622926</ArticleId></ArticleIdList></Reference><Reference><Citation>Kida S, Steart PV, Zhang ET, Weller RO. Perivascular cells act as scavengers in the cerebral perivascular spaces and remain distinct from pericytes, microglia and macrophages. Acta Neuropathol. 1993;85:646&#x2013;652. doi: 10.1007/BF00334675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00334675</ArticleId><ArticleId IdType="pubmed">8337943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl Acad. Sci. USA. 2009;106:1261&#x2013;1266. doi: 10.1073/pnas.0805453106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0805453106</ArticleId><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="pubmed">19164591</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraci FM. Disease highlights the cellular diversity of neurovascular units: sign in stranger. Circ. Res. 2017;121:203&#x2013;205. doi: 10.1161/CIRCRESAHA.117.311386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.311386</ArticleId><ArticleId IdType="pmc">PMC5539904</ArticleId><ArticleId IdType="pubmed">28729449</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, et al. Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer abeta peptides. Circ. Res. 2017;121:258&#x2013;269. doi: 10.1161/CIRCRESAHA.117.311054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.311054</ArticleId><ArticleId IdType="pmc">PMC5522360</ArticleId><ArticleId IdType="pubmed">28515043</ArticleId></ArticleIdList></Reference><Reference><Citation>Drieu A, et al. Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid. Nature. 2022;611:585&#x2013;593. doi: 10.1038/s41586-022-05397-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05397-3</ArticleId><ArticleId IdType="pmc">PMC9899827</ArticleId><ArticleId IdType="pubmed">36352225</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccazzi M, Raffaele S, Fumagalli M. Not only myelination: the immune-inflammatory functions of oligodendrocytes. Neural Regen. Res. 2022;17:2661&#x2013;2663. doi: 10.4103/1673-5374.342678.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.342678</ArticleId><ArticleId IdType="pmc">PMC9165378</ArticleId><ArticleId IdType="pubmed">35662200</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177. doi: 10.1038/22124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/22124</ArticleId><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46&#x2013;54. doi: 10.1212/01.WNL.0000073623.84147.A8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000073623.84147.A8</ArticleId><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantile, F. &amp; Prisco, A. Vaccination against beta-amyloid as a strategy for the prevention of Alzheimer&#x2019;s disease. Biology (Basel)9 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7761159</ArticleId><ArticleId IdType="pubmed">33260956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer&#x2019;s disease. Nature. 2016;537:50&#x2013;56. doi: 10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer&#x2019;s disease. J. Prev. Alzheimers Dis. 2022;9:197&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">35542991</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs Context. 2021;10:2021-7-3. doi: 10.7573/dic.2021-7-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.7573/dic.2021-7-3</ArticleId><ArticleId IdType="pmc">PMC8491638</ArticleId><ArticleId IdType="pubmed">34650610</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH, et al. Lecanemab in early Alzheimer&#x2019;s disease. N. Engl. J. Med. 2023;388:9&#x2013;21. doi: 10.1056/NEJMoa2212948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2212948</ArticleId><ArticleId IdType="pubmed">36449413</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2018;14:399&#x2013;415. doi: 10.1038/s41582-018-0013-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0013-z</ArticleId><ArticleId IdType="pmc">PMC6463489</ArticleId><ArticleId IdType="pubmed">29895964</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007;27:9115&#x2013;9129. doi: 10.1523/JNEUROSCI.2361-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2361-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenmann H, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 2006;63:1459&#x2013;1467. doi: 10.1001/archneur.63.10.1459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.10.1459</ArticleId><ArticleId IdType="pubmed">17030663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozenstein-Tsalkovich L, et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp. Neurol. 2013;248:451&#x2013;456. doi: 10.1016/j.expneurol.2013.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.07.006</ArticleId><ArticleId IdType="pubmed">23876516</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina M, Avila J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front. Cell. Neurosci. 2014;8:113. doi: 10.3389/fncel.2014.00113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00113</ArticleId><ArticleId IdType="pmc">PMC4005959</ArticleId><ArticleId IdType="pubmed">24795568</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul R, et al. INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer&#x2019;s disease. Neurology. 2021;17:e054615.</Citation></Reference><Reference><Citation>Wang S, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer&#x2019;s disease model. J. Exp. Med. 2020;217:e20200785. doi: 10.1084/jem.20200785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200785</ArticleId><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference><Reference><Citation>Voytyuk I, De Strooper B, Chavez-Gutierrez L. Modulation of gamma- and beta-secretases as early prevention against Alzheimer&#x2019;s disease. Biol. Psychiatry. 2018;83:320&#x2013;327. doi: 10.1016/j.biopsych.2017.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.08.001</ArticleId><ArticleId IdType="pubmed">28918941</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 2020;12:e11227. doi: 10.15252/emmm.201911227.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911227</ArticleId><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch KM, et al. Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice. Proc. Natl. Acad. Sci. USA. 2021;118:e2100356118. doi: 10.1073/pnas.2100356118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2100356118</ArticleId><ArticleId IdType="pmc">PMC8271763</ArticleId><ArticleId IdType="pubmed">34187891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivers-Auty J, Mather AE, Peters R, Lawrence CB, Brough D. Anti-inflammatories in Alzheimer&#x2019;s disease-potential therapy or spurious correlate? Brain Commun. 2020;2:fcaa109. doi: 10.1093/braincomms/fcaa109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa109</ArticleId><ArticleId IdType="pmc">PMC7585697</ArticleId><ArticleId IdType="pubmed">33134914</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, et al. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2020;77:164&#x2013;174. doi: 10.1001/jamaneurol.2019.3762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3762</ArticleId><ArticleId IdType="pmc">PMC6865324</ArticleId><ArticleId IdType="pubmed">31738372</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccioni RB, Calfio C, Gonzalez A, Luttges V. Novel nutraceutical compounds in Alzheimer prevention. Biomolecules. 2022;12:249. doi: 10.3390/biom12020249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12020249</ArticleId><ArticleId IdType="pmc">PMC8961630</ArticleId><ArticleId IdType="pubmed">35204750</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman-Martinez L, et al. Interventional study to evaluate the clinical effects and safety of the nutraceutical compound BrainUp-10(R) in a cohort of patients with Alzheimer&#x2019;s disease: a multicenter, randomized, double-blind, and placebo-controlled trial. J. Alzheimer&#x2019;s Dis. 2021;81:1231&#x2013;1241. doi: 10.3233/JAD-201501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-201501</ArticleId><ArticleId IdType="pubmed">33935080</ArticleId></ArticleIdList></Reference><Reference><Citation>Feigin A, et al. Pepinemab antibody blockade of SEMA4D in early Huntington&#x2019;s disease: a randomized, placebo-controlled, phase 2 trial. Nat. Med. 2022;28:2183&#x2013;2193. doi: 10.1038/s41591-022-01919-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01919-8</ArticleId><ArticleId IdType="pmc">PMC9361919</ArticleId><ArticleId IdType="pubmed">35941373</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W, et al. Deciphering the roles of metformin in Alzheimer&#x2019;s disease: a snapshot. Front. Pharmacol. 2021;12:728315. doi: 10.3389/fphar.2021.728315.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.728315</ArticleId><ArticleId IdType="pmc">PMC8829062</ArticleId><ArticleId IdType="pubmed">35153733</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A. Progranulin as a therapeutic target in neurodegenerative diseases. Trends Pharmacol. Sci. 2022;43:641&#x2013;652. doi: 10.1016/j.tips.2021.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2021.11.015</ArticleId><ArticleId IdType="pubmed">35039149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, et al. Cognitive changes with omega-3 polyunsaturated fatty acids in non-demented older adults with low omega-3 index. J. Nutr. Health Aging. 2017;21:988&#x2013;993. doi: 10.1007/s12603-017-0957-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-017-0957-5</ArticleId><ArticleId IdType="pubmed">29083439</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips MA, Childs CE, Calder PC, Rogers PJ. No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer&#x2019;s disease: a randomised controlled trial. Int. J. Mol. Sci. 2015;16:24600&#x2013;24613. doi: 10.3390/ijms161024600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms161024600</ArticleId><ArticleId IdType="pmc">PMC4632767</ArticleId><ArticleId IdType="pubmed">26501267</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabue-Teguo M, et al. Effect of multidomain intervention, omega-3 polyunsaturated fatty acids supplementation or their combinaison on cognitive function in non-demented older adults according to frail status: results from the MAPT study. J. Nutr. Health Aging. 2018;22:923&#x2013;927. doi: 10.1007/s12603-018-1024-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-018-1024-6</ArticleId><ArticleId IdType="pubmed">30272094</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurko-Mauro K, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6:456&#x2013;464. doi: 10.1016/j.jalz.2010.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.01.013</ArticleId><ArticleId IdType="pubmed">20434961</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn JF, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304:1903&#x2013;1911. doi: 10.1001/jama.2010.1510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.1510</ArticleId><ArticleId IdType="pmc">PMC3259852</ArticleId><ArticleId IdType="pubmed">21045096</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Restrepo L, Pellegrini M. Immunotherapy of mild cognitive impairment by omega-3 supplementation: why are amyloid-beta antibodies and omega-3 not working in clinical trials? J. Alzheimer&#x2019;s Dis. 2018;62:1013&#x2013;1022. doi: 10.3233/JAD-170579.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170579</ArticleId><ArticleId IdType="pmc">PMC5870008</ArticleId><ArticleId IdType="pubmed">29103035</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson&#x2019;s disease. Neuron. 2005;46:857&#x2013;868. doi: 10.1016/j.neuron.2005.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.05.010</ArticleId><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghochikyan A, et al. Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human alpha-synuclein: feasibility study. Neurosci. Lett. 2014;560:86&#x2013;91. doi: 10.1016/j.neulet.2013.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.12.028</ArticleId><ArticleId IdType="pmc">PMC3928627</ArticleId><ArticleId IdType="pubmed">24361548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandler M, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson&#x2019;s disease clinical trials. Acta Neuropathol. 2014;127:861&#x2013;879. doi: 10.1007/s00401-014-1256-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1256-4</ArticleId><ArticleId IdType="pmc">PMC4034750</ArticleId><ArticleId IdType="pubmed">24525765</ArticleId></ArticleIdList></Reference><Reference><Citation>Villadiego J, et al. Immunization with alpha-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model. Glia. 2018;66:191&#x2013;205. doi: 10.1002/glia.23237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23237</ArticleId><ArticleId IdType="pubmed">29024008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zella SMA, et al. Emerging immunotherapies for Parkinson disease. Neurol. Ther. 2019;8:29&#x2013;44. doi: 10.1007/s40120-018-0122-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-018-0122-z</ArticleId><ArticleId IdType="pmc">PMC6534677</ArticleId><ArticleId IdType="pubmed">30539376</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson&#x2019;s disease. Sci. Rep. 2018;8:16165. doi: 10.1038/s41598-018-34490-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-34490-9</ArticleId><ArticleId IdType="pmc">PMC6212487</ArticleId><ArticleId IdType="pubmed">30385782</ArticleId></ArticleIdList></Reference><Reference><Citation>Cankaya S, Cankaya B, Kilic U, Kilic E, Yulug B. The therapeutic role of minocycline in Parkinson&#x2019;s disease. Drugs Context. 2019;8:212553. doi: 10.7573/dic.212553.</Citation><ArticleIdList><ArticleId IdType="doi">10.7573/dic.212553</ArticleId><ArticleId IdType="pmc">PMC6408180</ArticleId><ArticleId IdType="pubmed">30873213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurkowska-Jastrzebska I, et al. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson&#x2019;s disease. Int. Immunopharmacol. 2004;4:1307&#x2013;1318. doi: 10.1016/j.intimp.2004.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2004.05.006</ArticleId><ArticleId IdType="pubmed">15313429</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J. Pharm. Exp. Ther. 2000;293:607&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">10773035</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, et al. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson&#x2019;s disease. J. Neuroimmunol. 2021;354:577543. doi: 10.1016/j.jneuroim.2021.577543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577543</ArticleId><ArticleId IdType="pubmed">33714750</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, et al. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. Autophagy. 2019;15:1860&#x2013;1881. doi: 10.1080/15548627.2019.1596481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1596481</ArticleId><ArticleId IdType="pmc">PMC6844502</ArticleId><ArticleId IdType="pubmed">30966861</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari A, Yazdanpanah N, Rezaei N. The role of Toll-like receptors and neuroinflammation in Parkinson&#x2019;s disease. J. Neuroinflamm. 2022;19:135. doi: 10.1186/s12974-022-02496-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02496-w</ArticleId><ArticleId IdType="pmc">PMC9172200</ArticleId><ArticleId IdType="pubmed">35668422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, et al. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation. Mol. Neurodegener. 2018;13:43. doi: 10.1186/s13024-018-0276-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0276-2</ArticleId><ArticleId IdType="pmc">PMC6085656</ArticleId><ArticleId IdType="pubmed">30092810</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniele SG, et al. Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci. Signal. 2015;8:ra45. doi: 10.1126/scisignal.2005965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2005965</ArticleId><ArticleId IdType="pmc">PMC4601639</ArticleId><ArticleId IdType="pubmed">25969543</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, et al. Phosphorylated alpha-synuclein aggregated in Schwann cells exacerbates peripheral neuroinflammation and nerve dysfunction in Parkinson&#x2019;s disease through TLR2/NF-kappaB pathway. Cell Death Discov. 2021;7:289. doi: 10.1038/s41420-021-00676-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00676-w</ArticleId><ArticleId IdType="pmc">PMC8511120</ArticleId><ArticleId IdType="pubmed">34642321</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YL, et al. Kaempferol attenuates LPS-induced striatum injury in mice involving anti-neuroinflammation, maintaining BBB integrity, and down-regulating the HMGB1/TLR4 pathway. Int. J. Mol. Sci. 2019;20:491. doi: 10.3390/ijms20030491.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20030491</ArticleId><ArticleId IdType="pmc">PMC6386879</ArticleId><ArticleId IdType="pubmed">30678325</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui B, Guo X, You Y, Fu R. Farrerol attenuates MPP(+) -induced inflammatory response by TLR4 signaling in a microglia cell line. Phytother. Res. 2019;33:1134&#x2013;1141. doi: 10.1002/ptr.6307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.6307</ArticleId><ArticleId IdType="pubmed">30734970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng KW, Zhang T, Fu H, Liu GX, Wang XM. Schisandrin B exerts anti-neuroinflammatory activity by inhibiting the Toll-like receptor 4-dependent MyD88/IKK/NF-kappaB signaling pathway in lipopolysaccharide-induced microglia. Eur. J. Pharmacol. 2012;692:29&#x2013;37. doi: 10.1016/j.ejphar.2012.05.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2012.05.030</ArticleId><ArticleId IdType="pubmed">22698579</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza-Salazar FJ, Lezama-Toledo AR, Rivera-Monroy G, Borlongan CV. Exendin-4 for Parkinson&#x2019;s disease. Brain Circ. 2021;7:41&#x2013;43. doi: 10.4103/bc.bc_21_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/bc.bc_21_21</ArticleId><ArticleId IdType="pmc">PMC8057099</ArticleId><ArticleId IdType="pubmed">34084977</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun SP, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson&#x2019;s disease. Nat. Med. 2018;24:931&#x2013;938. doi: 10.1038/s41591-018-0051-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0051-5</ArticleId><ArticleId IdType="pmc">PMC6039259</ArticleId><ArticleId IdType="pubmed">29892066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhang L, Li L, Holscher C. Semaglutide is neuroprotective and reduces alpha-synuclein levels in the chronic MPTP mouse model of Parkinson&#x2019;s disease. J. Parkinsons Dis. 2019;9:157&#x2013;171. doi: 10.3233/JPD-181503.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-181503</ArticleId><ArticleId IdType="pubmed">30741689</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijiaratnam N, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson&#x2019;s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: the &#x2019;Exenatide-PD3&#x2019; study. BMJ Open. 2021;11:e047993. doi: 10.1136/bmjopen-2020-047993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-047993</ArticleId><ArticleId IdType="pmc">PMC8166598</ArticleId><ArticleId IdType="pubmed">34049922</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco R. T-cell based immunotherapies for Parkinson&#x2019;s disease. Explor. Neuroprotective Ther. 2021;1:72&#x2013;85. doi: 10.37349/ent.2021.00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.37349/ent.2021.00007</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Shukla S. Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis. Pharmaceuticals (Basel) 2020;14:29. doi: 10.3390/ph14010029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14010029</ArticleId><ArticleId IdType="pmc">PMC7823603</ArticleId><ArticleId IdType="pubmed">33396271</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaja-Capdevila N, Hernandez N, Navarro X, Herrando-Grabulosa M. Sigma-1 receptor is a pharmacological target to promote neuroprotection in the SOD1(G93A) ALS mice. Front. Pharmacol. 2021;12:780588. doi: 10.3389/fphar.2021.780588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.780588</ArticleId><ArticleId IdType="pmc">PMC8702863</ArticleId><ArticleId IdType="pubmed">34955848</ArticleId></ArticleIdList></Reference><Reference><Citation>Potenza RL, et al. Fingolimod: a disease-modifier drug in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics. 2016;13:918&#x2013;927. doi: 10.1007/s13311-016-0462-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0462-2</ArticleId><ArticleId IdType="pmc">PMC5081121</ArticleId><ArticleId IdType="pubmed">27456702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>